Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Bradley A. Bart, M.D., F.A.C.C. 5. TEACHING a. Percent effort - 25% b. Narrative summary Since joining the faculty in 1997, I have been engaged with teaching at all levels of graduate medical education through my involvement with medical students at the University of Minnesota; residents from the Internal Medicine, Family Medicine, and Emergency Medicine residency training programs at HCMC; cardiology fellows from the University of Minnesota; and, more recently, from a new fellowship training program in cardiovascular disease based at HCMC. FELLOWS HCMC was one of the key sites for clinical rotations for the University of Minnesota cardiology fellowship until 2010. From 2001 to 2010, I served as the site rotation director for the cardiology fellows' clinical rotations at HCMC, coordinating the rotations, educational programing, and evaluations for the University fellows that rotated at HCMC (36 fellow rotations per year). I also served on the fellowship selection committee for the University of Minnesota and committed approximately 30 hours per year reviewing application folders, interviewing prospective fellows, and ranking fellows for the match in committee meetings that took place every Fall. From 2002 to 2007, I was the Director of Nuclear Cardiac Imaging at the University of Minnesota, developed the nuclear cardiology curriculum for the University fellows, and taught the fellows weekly on site at the University of Minnesota. In addition to these leadership roles within the University fellowship program, I rounded and taught University fellows during their rotations at HCMC 10 weeks per year on the inpatient cardiology consultation service, once a week year round in the cardiac catheterization laboratory until 2008, and 1/2 day per week in the fellows' continuity clinic. I was also asked to lecture regularly on heart failure and nuclear cardiac imaging to the fellows during their weekly core curriculum sessions. In 2006, I was recognized as 'Teacher of the Year' by the University of Minnesota cardiology fellows. In 2010, I completed the ACGME Program Information Form (PIF) and application for a fellowship training program in cardiovascular disease based at HCMC. The application was successful and we became one of four newly accredited cardiovascular training programs in the United States that year. I am the fellowship Program Director, the chair of the fellowship Clinical Competency Committee, the chair of the Program Evaluation Committee, and serve on the HCMC Graduate Education Committee. We recruited our first class of entering Fellows in 2011 and will be graduating this inaugural class in June 2014. One graduating fellow will be starting an interventional fellowship at Duke University after graduation and the other fellow will be starting an electrophysiology fellowship at Kaiser Permanente. This fellowship has been a successful collaboration with the GME office at HCMC, the internal medicine residency program at HCMC, and the Minneapolis Heart Institute, the major rotating site outside HCMC. Our fellowship training program combines the history and culture of a public safety net and 1 teaching hospital (HCMC) and the strengths and procedural volumes of a thriving cardiology private practice - part of one of the largest referring networks in the state. The responsibility of the Program Director is oversight of all the educational content for the fellows as well as adherence to all the ACGME program requirements. I established 12 clinical rotations between two major hospitals, a research elective, and an international experience available to all fellows. I also established a weekly core curriculum involving 1 month of boot camp directed toward incoming fellows and a 40 week program divided into 4 major educational themes involving 10 lectures each: ischemic heart disease, heart failure, electrophysiology, and valvular/congenital heart disease. In addition to these leadership responsibilities, I continue to teach the fellows directly in the setting of weekly conferences, journal club, ECG reading sessions, and core lectures. In addition, I am the rotation director of the nuclear cardiology and advanced imaging rotation (2 months per year) and am a clinic preceptor for a cardiology fellow's continuity clinic (1/2 day per week). I also teach the fellows during the inpatient cardiology consultation service (10 weeks per year, 10 fellows per year). RESIDENTS In addition to my responsibilities as program director for the training program in cardiovascular disease, I maintain direct teaching responsibility in a number of clinical services in the hospital. I am the attending on the inpatient cardiology consultation service 10 weeks a year. This is a traditional academic rotating consultative service involving one fellow, three residents, and two medical students (approximately 60 trainees per year). I am a preceptor for residents interested in gaining experience in the Early Access cardiology clinic. I also give core lectures for the Internal Medicine residency program on heart failure and stress testing each year. MEDICAL STUDENTS I enjoy working with University of Minnesota second-year medical students in the small group sessions of the second year pathophysiology course on cardiovascular disease. Each year I lead a small group of 20 to 30 students through 3 to 6 sessions. For a number of years, I gave the heart failure and cardiomyopathy lectures in the 2nd year pathophysiology course at the University of Minnesota. I also teach medical students on the inpatient cardiology consultation service 10 weeks per year. RESEARCH WITH TRAINEES I have worked with residents and fellows on a number of clinically related research topics and these papers have been published or presented at national meetings in the following areas: nuclear cardiac imaging and balanced ischemia, prosthetic valve thrombosis, atrial fibrillation, radiation-induced myocardial stunning, use of therapeutic hypothermia in out of hospital cardiac arrest patients, the appropriateness of routine head CT scanning for out of hospital cardiac arrest patients, troponin elevations and pulmonary embolism, pulmonary hypertension, the effects of external counterpulsation on peripheral arterial disease, heart failure hospitalizations in cocaine users, the occurrence of coronary artery aneurysms in cocaine users, ultrafiltration, carotid artery stiffness, the use of mineralocorticoid receptor antagonists in heart failure, and the occurrence of a rare complication from septal myomectomy. 2 c. Teaching Experience Teaching Table I. Undergraduates Course Role Hours of time/year (number of lectures, etc) # of Students Years Taught Course Role Hours of time/year (number of lectures, etc) # of Students Years Taught Year II Med School Pathophys heart failure talk Year II Med School Pathophys sm group sessions Cardiology consult service Core curriculum stress testing/heart failure HCMC Speaker 2 per year Total 1000 8 Speaker/ facilitator 3-6 per year Total 900 13 Attending 10 weeks per year Total 320 16 Speaker 2 per year Total 850 16 Role Hours of time/year (number of lectures, etc) # of Students Years Taught Cardiorenal syndrome U of M and HCMC Myocardial viability U of M Myocardial perfusion imaging U of M Cardiology consult service HCMC Friday School Intern program HCMC Core curriculum stress testing/heart failure HCMC Nuclear cardiology U of M and HCMC Cardiac catheterization laboratory Cardiology clinic Speaker 1 per year Total 30-100 5 Speaker 1 per year Total 72-240 12 Speaker 2 per year Total 60-200 10 Attending 10 weeks per year Total 640 16 Speaker/facilitator 1 per year Total 50 3 Speaker 2 per year Total 850 16 Rotation Director 2-6 months per yr Total 70 7 Procedural attending Preceptor 44 days/year Total 120 11 ½ day/week Total 6 IV. Other Teaching/Activities (list) Medicine Grand Rounds Web-based learning – MIBI of the Month CV fellowship – all educational aspects Role Hours of time/year (number of lectures, etc.) # of Students Years Taught Speaker Various topics – 17 over the years Total 800-1600 16 Content leader 1 per month Total 1200 5 Program Director 25% overall time Total 14 3 None II. Graduates III. Pre/Post-Doctoral Classroom or Clinical 3 Mentoring/Training Table I. Undergraduate Students Role Trainee Name Training Period Where Trained Project Academic Level of Trainee Present Position and Institution Training Period Where Trained Project Academic Level of Trainee Present Position and Institution Project Present Position and Institution None II. Graduate Trainees Role Trainee Name None III. Post-Doctoral Trainees Role Trainee Name Training Period Where Trained Program Director Program Director Program Director Ben Johnson 2014 HCMC Academic Level of Trainee PGY 4 Michelle Carlson Sarah Thordsen 2014 HCMC PGY 4 2013present HCMC Program Director Program Director Program Director and clinic preceptor Yader Sandoval Amatul Hassan Ankur Kalra 2013present 2012present 2012present HCMC Program Director and clinic preceptor Program Director and clinic preceptor Advisor and research mentor Clinic preceptor Clinic preceptor Louis Kohl 20112014 HCMC Hemal Kadakia 20112014 Imdad Ahmed Cardiology Fellow – HCMC Cardiology Fellow – HCMC Cardiology Fellow – HCMC Eplerenone use in chronic heart failure JACC 2013 QTc intervals in hypothermia Career and research advisor Aorto-right atrial fistula after cardiac surgery Echocardiography 2012 Career and research advisor PGY 4,5 HCMC Career and research advisor PGY 4-6 EP Fellow – Kaiser Permanente, LA, California 2010 Regions Heart failure in cocaine users JCF 2010 Electrophysiology Yale Joseph Browning Santiago Garcia 20092010 20082009 U of Minnesota Hospitalists with Health Partners PGY 4-6 U of Minnesota PGY 4-6 Clinic preceptor Darshak Karia 20032005 U of Minnesota PGY 4-6 Advisor and research collaborator Marit Thorsgard 20062009 HCMC HCMC HCMC Ultrafiltration for heart failure Congest Heart Fail 2009 4 PGY 4,5 PGY 4-6 PGY 4-6 PGY 4-6 PGY 4-6 Cardiology Fellow – HCMC Cardiology Fellow – HCMC Cardiology Fellow – HCMC – accepted to Interventional CV Fellowship – Beth Israel, Boston Interventional CV Fellow – Duke University Cardiology – Health Partners Interventional Cardiology – Minneapolis VAMC Heart Failure specialists –Einstein Medical Center, Philadelphia Interventional Cardiology – Health Partners Advisor and research mentor Gautam Shroff 20032006 HCMC Clinic preceptor Ganesh Raveendrum 20022003 U of Minnesota Advisor and research collaborator Aimee Koralesky 19992002 HCMC Advisor and research mentor James Mohn 19992002 U of Minnesota Advisor and research collaborator Aaron Satran 19972000 HCMC Advisor and imaging mentor James Montana 1999 HCMC Training Period Where Trained Carotid artery stiffness and risk of coronary heart disease ACC 2005, J of Hum Hypertens 2009 PGY 1-3 Echo director - HCMC PGY 4-6 Interventional Cardiology and Program Director, U of Minnesota Non-invasive Cardiology – Minneapolis Role of troponin I in predicting outcomes after pulmonary embolism World Congress, Australia 2002, JACC 2002 Echocardiographic correlates of pulmonary hypertension ACC 2004 Incidence of coronary artery aneurism formation in cocaine users ACC 1998, Circulation 1999 Level II training in nuclear cardiology PGY 1-3 Project PGY 4-6 Interventional Cardiology - St. Luke’s Cardiology, Duluth PGY 1-3 Interventional Cardiology – Louisville Heart Specialists PGY 7 Primary Care – Essential Health Academic Level of Trainee Present Position and Institution IV. Junior Faculty Trainees Role Trainee Name See above Teaching/Instructional/Educational Activity University of Minnesota Course/Lecture List “Cardiorenal Syndrome and Ultrafiltration,” University of Minnesota Cardiology Fellowship Training Program Core Conferences, University of Minnesota, Minneapolis, Minnesota, 2012. “Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010. “Myocardial Perfusion Defects,” University of Minnesota, Minneapolis, Minnesota, December 2010. “Stress Testing in ESRD Patients,” Imaging Conference, University of Minnesota, Minneapolis, Minnesota, January 27, 2010. “Valvular Heart Disease,” Clinical Cardiology Conference, Hennepin County Medical Center, Minneapolis, Minnesota, 2010. “Pathogenesis of Atherosclerosis,” Surgery Didactic Curriculum, Hennepin County Medical Center, Minneapolis, Minnesota, January 6, 2009. 5 “Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2005. “Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. “Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. “External Counterpulsation for the Treatment of Angina Pectoris,” Research Conference, Fairview-University Medical Center, Minneapolis, Minnesota, 2002. Year II Medical School Pathophysiology Course lectures on cardiomyopathy and heart failure (two lectures) each year from 2001 to 2008 (150 students per lecture). “Assessment of Myocardial Viability,” Interventional Cardiology Conference, University of Minnesota, Minneapolis, Minnesota, annually from 2000 to 2012. “Myocardial Perfusion Imaging” Core Curriculum, University of Minnesota Fellowship in Cardiovascular Disease, two lectures per year annually from 2000 to 2010. “Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2000. Year II Pathophysiology Small Group Sessions – 20-30 students per session, 3-6 sessions per year, from 1991 to present. Curriculum Development Pilot project for Cardiology Fellows’ end of rotation evaluations involving educational milestones encompassing the 6 ACGME core competencies, Hennepin County Medical Center, 2012-Present. Curriculum, learning objectives and expectations for each of the 6 ACGME core competencies for 12 clinical rotations between two major hospitals, a research elective, and an international experience available to all fellows for the HCMC Fellowship Training Program in Cardiovascular Disease, 2011-Present. Core curriculum for HCMC Training Program in Cardiovascular Disease involving 1 month of boot camp directed toward incoming fellows and a 40 week program divided into 4 major educational themes involving 10 lectures each: ischemic heart disease, heart failure, electrophysiology, and valvular/congenital heart disease, 2011-Present. Nuclear Cardiology curriculum, learning objectives and expectations for each of the 6 ACGME core competencies for the Cardiology Fellowship rotation in Nuclear Cardiology for the University of Minnesota, 2002-2007. Web-based learning activity for interpretation of SPECT images "MIBI of the Month,” University of Minnesota Cardiology Fellowship and Affiliate Faculty Members, 2001-2005. Collaborative Efforts and Activities Co-Chair, Interdepartmental Task Force for establishing improved relations with the Renal Transplant Service, 2013-Present. Co-Chair, Interdepartmental Task Force for establishing improved relations between Emergency Medicine and Cardiology, 2012-Present. Program Director of Fellowship Training Program in Cardiovascular Disease coordinating educational activities between two primary sites, Hennepin County Medical Center and Abbott Northwestern Hospital, 2011-Present. 6 Steering Committee Member, NHLBI Heart Failure Clinical Trials Network, 2006-2012. Minnesota Heart Failure Consortium Advisory Board Member, 2002-Present. Member, Hennepin Faculty Associates (HFA) Board of Directors representing the Department of Medicine, 2000-2003 and 2011-2012. Faculty Development Activities Regarding Teaching Annual attendance at "educating the educators" session for program directors in Fellowship training programs for cardiovascular disease, American College of Cardiology annual scientific sessions, 2011-Present. Organized, facilitated and educated faculty from Hennepin County Medical Center and Abbott Northwestern’s combined cardiology fellowship program during semiannual meetings related to the evaluation of the cardiology fellows, 2011-Present. Chair, Clinical Competency Committee and Program Evaluation Committee for the Fellowship training program and cardiovascular disease, 2011-Present. Continuing Medical Education (invited CME lectures) 1. “Hot Topics from the American College of Cardiology (ACC) 2014,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, April 24, 2014. 2. “Effect of heart failure treatment strategies on development of cardiorenal syndrome" 63rd annual scientific sessions of the American College of Cardiology, Washington DC, 2014. 3. "Rule of ultrafiltration in acute decompensated heart failure", joint symposium of the German cardiac Society and Thai Heart Association and the American College of Cardiology, 63rd annual scientific sessions of the American College of Cardiology, Washington DC, 2014. 4. “Heart Failure Trials: The Year in Review,” CARRESS-HF 17th Annual Scientific Meeting, Heart Failure Society of America, Orlando, Florida, September 23, 2013. 5. “Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome–The Creation of a Comparative Effectiveness Trial,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, December 6, 2012. 6. “Cardiorenal Syndrome: CARRESS HF Trial Results and Implications,” Heart Failure 2012: The Update, Minnesota Heart Failure Consortium, Edina, Minnesota, December 1, 2012. 7. “Advantages and Pitfalls of Ultrafiltration Therapy,” American College of Cardiology’s 61st Annual Scientific Sessions and Expo, Chicago, Illinois, March 25, 2012. 8. “Heart Failure and Renal Failure,” Heart Failure 2011: The Update, 9th Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota, October 29, 2011. 9. “Hemoconcentration with Ultrafiltration: Good or Bad?” 15th Annual Scientific Meeting, Heart Failure Society of America, Boston, Massachusetts, September 19, 2011. 10. “NHLBI Heart Failure Clinical Trials Network–Introduction to Selected Ongoing Trials at Hennepin County Medical Center,” Geriatrics Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, August 9, 2011. 11. “Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010. 12. “Should All Patients with Decompensated Heart Failure and Volume Overload Receive Ultrafiltration?” Debate, Pro: Bart BA, Con: Walsh M. Heart Failure 2009: The Update, 7th Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota, November 7, 2009. 7 13. “Wanted: Dead or Alive; Myocardial Viability Testing,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, December 11, 2008. 14. “Changes in Renal Function during Heart Failure Therapy: What is the Kidney Trying to Tell Us?” 30th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota, December 4, 2008. 15. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Heart Institute, Minneapolis, Minnesota, November 24, 2008. 16. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Veterans Medical Center, Minneapolis, Minnesota, November 21, 2008. 17. “Ultrafiltration for Heart Failure: Mechanisms and Benefits,” 29th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota, 2008. 18. “Management of Acute Fluid Overload: Diuretics vs. Aquaphoresis,” Transcatheter Cardiovascular Therapeutics (TCT) Meeting, Washington, DC, 2007. 19. “Ultrafiltration Benefits and Mechanisms,” Heart Failure Society of America, 11th Annual Scientific Meeting, Washington, DC, 2007. 20. “Heart Failure for the Consultant Cardiologist: 2007 Update,” Session Co-chair, 56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 2007. 21. “Managing CHF: Staying beyond the Hospital Walls,” Facilitator, Heart Center Conference, Roundtable Discussion, Durham, North Carolina, 1995. 22. “The Cardiologist’s Role in Heart Failure Stages A-D.” CME Program for Minnesota Chapter of the American College of Cardiology Annual Meeting, Minneapolis, Minnesota, 2006. 23. “Do All Patients with an EF <35% Need an ICD Device?” Debate Speaker, Pro: Alan Bank, Con: Bart BA, Heart Failure 2006: The Update, Bloomington, Minnesota, 2006. 24. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand Rounds, University of Illinois, Chicago, Illinois, 2006. 25. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2006. 26. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds, Veterans Administration Medical Center, Minneapolis, Minnesota, 2006. 27. External Counterpulsation Therapy for Ischemic Heart Disease,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2005. 28. “Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2005. 29. “Ultrafiltration in the Postoperative and Congestive Heart Failure Patients," Cardiology/Surgery Conference, United Hospital, Saint Paul, Minnesota, 2005. 30. “Assessment of Myocardial Viability,” Health Partners 28th Annual Cardiovascular Conference, Saint Paul, Minnesota, 2005. 31. “Meet the Thought Leaders and Industry Experts on EECP Therapy: A Noninvasive Therapy for Heart Failure and Angina Pectoris," Meet the Experts, American College of Cardiology, Satellite Symposia, Orlando, Florida, 2005. 32. “Does this Patient with Nonischemic Cardiomyopathy Need a Defibrillator?" Cardiology Conference, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, 2004. 8 33. “Should this Patient get a Defibrillator: Controversies in Cardiology," Scientific and Business Meeting, American College of Cardiology-Minnesota Chapter, Minneapolis, Minnesota, 2004. 34. “Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. 35. “Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. 36. “Therapeutic Ultrafiltration for the Management of Fluid Overload: Current and Future Role–The RAPID CHF Study,” Satellite Symposium, Heart Failure Society of America, Las Vegas, Nevada, 2003. 37. “Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2000. 38. “Angiotensin Receptor Blockers: Mechanisms and New Directions,” Grand Rounds, Veterans Administration Medical Center, Minneapolis, Minnesota, 1998. 39. “Nuclear Cardiac Imaging,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 1997. 40. “Management of Heart Failure,” Panelist, 15th Edward S. Orgain Cardiovascular Symposium, Durham, North Carolina, 1996. d. Teaching Effectiveness New Innovations RMS Evaluations—HCMC-IM-CARD Co, Fellow Evaluation Summary for time period 7/1/2006 to 6/30/2014 (Evaluation Scale: 5=high, 1=low) Date Topic Evaluation # of Scores Evaluations 7/1/2011‐ Patient care – Supervises and provides compassionate, 4.50 6 6/30/2012 appropriate and effective patient care in all settings 7/1/2011‐ Medical Knowledge – Current with recent advances and 5.00 6 6/30/2012 demonstrates knowledge of current clinical guidelines 4.50 6 7/1/2011‐ Practice‐Based Learning and Improvement – Investigates 6/30/2012 and evaluates patient care appraisal and assimilation of scientific evidence and advances 7/1/2011‐ Systems Based Practice – Insures timely and continuous 5.00 6 6/30/2012 care, demonstrates awareness of and responsiveness 7/1/2011‐ Interpersonal and Communication Skills – Demonstrates 4.50 6 6/30/2012 skills with patients, residents, patient’s care team and hospital staff 7/1/2011‐ Professionalism – Projects positive image 4.50 6 6/30/2012 7/1/2011‐ Teaching‐appropriate guidance and feedback 4.50 6 6/30/2012 7/1/2011‐ Availability – Prompt, spent enough time on rounds, 4.50 6 6/30/2012 focused 7/1/2011‐ Availability – Reviewed expectations, provided feedback, 4.50 6 6/30/2012 give positive reinforcement 9 New Innovations RMS Evaluations—HCMC-IM-BLUE 1; HCMC-IM BLUE2; HCMC-IM-CARD CON, Resident Evaluation Summary for time period 7/1/2006-6/30/2014 (Evaluation Scales: 5=high. 1=low, or 3=high, 1=low) Date Topic Evaluation # of Scores Evaluations 7/1/2006‐ Communication with residents and primary team (3‐1) 89 6/30/2014 2.81 7/1/2006‐ Rounding & Teaching (3‐1) 89 6/30/2014 2.92 7/1/2006‐ Overall (5‐1) 89 6/30/2014 4.83 7/1/2006‐ Patient Care‐ provides compassionate, appropriate and (5‐1) 89 6/30/2014 effective patient care 4.60 7/1/2006‐ Medical Knowledge‐Stays current with medical (5‐1) 89 6/30/2014 advances and demonstrates knowledge of current 4.63 clinical guidelines 7/1/2006‐ Practice‐Based Learning and Improvement‐investigates (5‐1) 89 6/30/2014 and evaluates their own patient care 4.54 7/1/2006‐ Systems Based Practice‐Insures timely and continuous (5‐1) 89 6/30/2014 care of patients at all times 4.56 (5‐1) 89 7/1/2006‐ Interpersonal and Communication Skills‐demonstrates 4.54 6/30/2014 communication skills with patients, families, fellow providers, referring physicians, residents etc. (5‐1) 89 7/1/2006‐ Professionalism‐respectful of residents, staff and 4.65 6/30/2014 patients regardless of age, gender, religious or cultural difference 7/1/2006‐ Teaching‐provides appropriate guidance and feedback (5‐1) 89 6/30/2014 in patient management 4.61 7/1/2006‐ Availability‐prompt, adhered to rounds schedule, kept (5‐1) 89 6/30/2014 interruptions to minimum, appeared unhurried, focused 4.52 7/1/2006‐ Availability – Reviewed expectations, provided (5‐1) 89 6/30/2014 feedback, give positive reinforcement 4.38 7/1/2006‐ Patient Care‐ provides compassionate, appropriate and (5‐1) 89 6/30/2014 effective patient care 4.61 7/1/2006‐ Medical Knowledge‐Stays current with medical (5‐1) 89 6/30/2014 advances and demonstrates knowledge of current 4.66 clinical guidelines 7/1/2006‐ Practice‐Based Learning and Improvement‐investigates (5‐1) 89 6/30/2014 and evaluates their own patient care 4.75 7/1/2006‐ Systems Based Practice‐Insures timely and continuous (5‐1) 89 6/30/2014 care of patients at all times 4.75 10 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 7/1/2006‐ 6/30/2014 Interpersonal and Communication Skills‐demonstrates communication skills with patients, families, fellow providers, referring physicians, residents etc. Professionalism‐respectful of residents, staff and patients regardless of age, gender, religious or cultural difference Teaching‐provides appropriate guidance and feedback in patient management Availability‐prompt, adhered to rounds schedule, kept interruptions to minimum, appeared unhurried, focused Overall Availability‐prompt, adhered to rounds schedule, kept interruptions to minimum, appeared unhurried, focused Availability – Reviewed expectations, provided feedback, give positive reinforcement Systems Based Practice‐Insures timely and continuous care of patients at all times Practice‐Based Learning and Improvement‐investigates and evaluates their own patient care Teaching‐provides appropriate guidance and feedback in patient management Medical Knowledge‐Stays current with medical advances and demonstrates knowledge of current clinical guidelines Interpersonal and Communication Skills‐demonstrates communication skills with patients, families, fellow providers, referring physicians, residents etc. Professionalism‐respectful of residents, staff and patients regardless of age, gender, religious or cultural difference Teaching‐provides appropriate guidance and feedback in patient management Medical Knowledge‐Stays current with medical advances and demonstrates knowledge of current clinical guidelines Patient Care‐ provides compassionate, appropriate and effective patient care Overall –evaluation of faculty Overall – rate your learning experience 11 (5‐1) 4.57 89 (5‐1) 4.66 89 (5‐1) 4.52 (5‐1) 4.59 (5‐1) 4.46 (5‐1) 4.65 (5‐1) 4.53 (5‐1) 4.55 (5‐1) 4.60 (5‐1) 4.69 (5‐1) 4.77 89 89 89 89 89 89 89 89 89 (5‐1) 4.57 89 (5‐1) 4.66 89 (5‐1) 4.69 (5‐1) 4.77 89 (5‐1) 4.76 (5‐1) 4.69 (5‐1) 4.39 89 89 89 89 Evaluator Comments: Efficient at both patient care and teaching. Very approachable and goes out of his way to teach. AND it’s HIGH‐YIELD learning!! Excellent teacher – makes points to patient problems and articulated in a very clear manner. Thank you for taking the time to do extra teaching on a slow week. This rotation is top 3 in the hospital. Fun to work with. I feel like I learned something new every day. Dr. Bart is good at including the whole team in discussions on our patients during rounds. Really great working with Dr. Bart. He is very patient and thorough and teaches effectively. Dr. Bart is really an outstanding teacher. He is patient during resident presentations, elicits our care plan, and expands on our plan to provide teaching points on each individual patient. It’s my pleasure working with Dr. Bart. He is a great teacher and very collegial with residents. Looking forward to work with him again. Dr. Bart allowed residents to formulate plan, took time to explain the reasoning behind the recommendations, also he was focused on case based teaching which made the whole experience invaluable! Very knowledgeable, dedicated, and pleasant. Great week, one of the best teachers I have had. The only criticism that I would give is to make sure and let the resident and/or student make their assessment and plan known before jumping in. For confident students and residents, it doesn’t matter much, but for others it is important that you not only let them, but make them have an assessment and plan before outlining THE plan. Good teaching points, took his time with questions, helpful in physical exam skills. Dr. Bart is extremely knowledgeable in his area, up to date with recent literature, and teaches very well. He found teaching points in every case we saw. Outstanding cardiology faculty to work with. Very knowledgeable in current guidelines and most relevant trial results. Took time to teach cardiac physiology relevant to our cases. Served as a good role model in compassionate patient care at the bedside. Overall, an outstanding clinician and instructor. Dr. Bart is a superb teacher. His clinical acumen and extensive knowledge, along with high expectations and a Socratic teaching method, make for an excellent clinical experience as a resident. It is a pleasure to work with him. It is great to work with Dr. Bart. He teaches using a Socratic method that engages and requires independent thought. He shows patients, residents and students respect and is a very effective teacher‐clinician. Dr. Bart provided excellent teaching on rounds and was very good about prompting the resident about what the diagnosis and treatment plan was instead of just telling us what he felt we should do. He is thoughtful and compassionate. I feel I learned a lot working with him. 12 Dr. Bart is such a great attending to work with, fun and professional. I always look forward to working cardiology. Dr. Bart once again taught me so much about cards. I am continuously humbled by the amount of learning in medicine and he highlights and encourages that thirst for knowledge and human betterment in us. Great teaching! Dr. Bart is a good teacher. I appreciated his impromptu lectures (white∙board talks) on various topics. Dr. Bart is a great teacher and clinician. He is always prompt and efficient and respectful of patients but also of residents and other staff. He is also great example of someone who practices medicine as an art. What struck me most while working with Dr. Bart was the amount of information we learned with each patient. Each patient cared for on the consult team is a gateway to education, and as a resident the value of that cannot be underestimated. He, and all of his colleagues in the cardiology department, are among those that make this a residency of the highest quality. Dr. Bart was very professional and helpful in sorting out consults. Very enjoyable to work with. It was a good learning experience with Dr. Bart. A model academic physician never hurried despite busy service. Really appreciate that Dr. Bart took the time to teach when things weren't as busy. An outstanding physician, cardiologist and teacher. I had the opportunity to learn from him three years in a row on cardiology and each year learned some more. He is an asset to the service. Thanks for the teaching. Efficient, great communication with consult team, treatment teams, patients and families. Great role model, encouraged residents to dig deeper and come up with plans, gently nudged them towards appropriate answer. Brad is fantastic, l have known him for 5 years and he has grown to be head of the CV Diseases Division and now Program Director of the Cardiology Program at HCMC/ANW without losing his collegial approach with staff and residents. It is commendable that in the midst of interview: season he was able to manage the busy Cardiology Consult Service in an impeccable way. 13 University of Minnesota Student Performance Analysis Report-Internal Medicine Clerkships Evaluation Summary for time period 1/1/1990-06/30/2014 Date Topic Evaluation Criteria Evaluation Scores (percentage) # of Evaluations # of Evaluations 1/1/1990‐ Overall Teaching Skill 06/30/2014 Outstanding 100% 2 1/1/1990‐ Organization for Teaching 06/30/2014 setting clear expectations. Outstanding 100% 2 1/1/1990‐ Communication of knowledge 06/30/2014 in presentations and in articulation of clinical reasoning process. Outstanding 100% 2 1/1/1990‐ Stimulation of Problem 06/30/2014 Solving asking effective questions. 1/1/1990‐ Supervision of Clinical Work 06/30/2014 direct supervision and observation of clinical work. Outstanding 100% 2 Outstanding 100% 2 1/1/1990‐ Appropriate Balance Allowed 06/30/2014 provision of an appropriate balance between responsibility and supervision. 1/1/1990‐ Feedback Effectiveness 06/30/2014 clear, specific, timely, constructive, ongoing. Outstanding 100% 2 Outstanding 100% 2 1/1/1990‐ Relationships with Students 06/30/2014 supportive, patient, empathetic, approachable, respectful, courteous, punctual, accessible for help, enthusiasm for teaching 1/1/1990‐ Role Model 06/30/2014 knowledge and competence as a physician, professionalism, relationship with patients and families. Outstanding 100% 2 Outstanding 100% 2 14 Group Comments: Strengths. Teaching Strengths Took a great deal of time to teach on rounds in the morning in general and paid the students a lot of attention in particular. I like his style of teaching informally on rounds in the morning. The best approach to teaching I encountered on this rotation. Excellent job of describing expectations at the beginning of his term and allowing students to initiate all the patient planning. Cardiology Pathophysiology Course, University of Minnesota, Cardiovascular Fellowship Course comments, November 2009 Comments Very good instructor. Fantastic! Best instructor I’ve had so far! Incredibly clear instruction. Really, really great pace and very helpful explanations. If we didn’t understand, he would take us back a step, walk us through so we were all on the same page and could learn the related material. Dr. Bart is one of the best instructors I have ever had. He taught the pathophysiology of the heart in a way that was clear and simple and thorough. His small group should be a model for the rest. Dr. Bart was an amazing small group leader. I’m sorry that I only got to attend his group once. Teaching /Instructional/Educations Activity Clinical Nephrology Conference at HCMC for Nephrology faculty, fellows, residents and medical students. Date Topic Evaluation Evaluation # of Critique Score Evaluations Excellent Good Depth of coverage 1/9/2009 Renal Denervation 17 2 19 Quality of presentation for Hypertension 17 2 Impact on patient care 14 5 Audiovisuals 17 2 How well did lecture meet objectives 18 1 Group Comments Very interesting, thank you. Awesome presentation, very interesting. Excellent conference. Excellent study, needs to come back yearly to follow the results of the study. Fantastic, very interesting! Thank you for coming and sharing with us. Early beneficial effects are considerable, interesting, will be interesting to see long term results. 15 16 Honors/Awards Received for Teaching Effectiveness University of Minnesota Teacher of the Year, University of Minnesota Cardiovascular Fellows, Minneapolis, Minnesota 19 2006-2007 Bradley A. Bart, M.D., F.A.C.C. 6. RESEARCH AND SCHOLARSHIP a. Percent effort 15% b. Narrative Summary I am a clinical cardiologist with an interest in heart failure. My colleague Steven Goldsmith and I developed a regional network of academic and non-academic institutions to facilitate collaboration on heart failure research. This network, the Minnesota Heart Failure Consortium, combined the talents and resources of most of the major heart failure research organizations in Minnesota; IRB approval, contracting, monitoring, protocol development and communications were streamlined to enhance our ability to efficiently perform industry sponsored trials as well as investigator initiated studies. The design and success of the Minnesota Heart Failure Consortium led to our successful application to the National Heart, Lung, and Blood Institute's Heart Failure Clinical Trials Network in 2006, one of 9 Regional Clinical Centers (RCCs) across the nation. The purpose of the NHLBI Heart Failure Network was to provide a mechanism to expedite clinical research that evaluates strategies to diagnose, manage and treat all forms of heart failure and the Minnesota RCC played a significant leadership role in the development of protocols and enrollment of patients. The Minnesota RCC was recognized by the NHLBI Heart Failure Network in 2010 with an award for excellence for achieving the best overall combination of enrollment and endpoint completion. I served on the national steering committee and as Principal or Coprincipal investigator for the Minnesota RCC sites for these trials. The first round of trials designed and executed by the NHLBI Heart Failure Network have been published in top-tier journals and have influenced the practice of medicine and the approach to treating patients with heart failure. These studies include: DOSE (NEJM 2011), CARRESS HF (NEJM 2012), RELAX (JAMA 2013), ROSE (JAMA 2013), and EXACT (manuscript in preparation). I have been interested in ultrafiltration as an alternative to loop diuretics for the treatment of congestion in heart failure since 2002. At that time, I designed and coordinated the first randomized controlled comparison of ultrafiltration versus IV diuretics in patients hospitalized with acute decompensated heart failure - the RAPID trial (JACC 2005). This was a successful feasibility study demonstrating that ultrafiltration could be safely performed in a multicenter study and provided valuable information needed to plan the much larger UNLOAD study (JACC 2007). I helped design the UNLOAD study, was on the national steering committee, and was the site PI at HCMC. UNLOAD stimulated national interest in ultrafiltration for acute heart failure.I wrote the protocol and served as the national PI for the CARRESS HF trial, a randomized controlled trial of ultrafiltration vs. stepped pharmacologic care in patients with acute heart failure and cardiorenal syndrome conducted by the NHLBI Heart Failure Network. CARRESS HF (NEJM 2012) has had a significant impact on the current use of ultrafiltration and has contributed significantly to ongoing debate regarding the indications and prescription of ultrafiltration in acute heart failure. Currently, I am on the national steering committee and am the site PI at HCMC for the AVOID trial - a trial of similar design to UNLOAD, but powered for heart failure events at 90 days as a primary endpoint (NCT01474200). As a result of this body of 1 work, ultrafiltration has been incorporated into the guidelines for the treatment of acute heart failure by the Heart Failure Society of America, the American College of Cardiology Foundation/American Heart Association, the Canadian Cardiovascular Society, the International Society of Heart and Lung Transplantation, and the European Society of Cardiology. I am recognized nationally and internationally as an expert in the area of ultrafiltration and other acute decongestive strategies for heart failure and have been invited to speak at the annual scientific sessions of the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America. I have been invited to write book chapters, editorials and perspective papers on ultrafiltration for the American Heart Journal, Cardiology Review, Congestive Heart Failure, the Journal of Cardiac Failure, the Journal of the American College of Cardiology, and Circulation Heart Failure. As a clinical trialist, I have also been the site PI or Co-PI on a number of other clinical trials dealing with heart failure. These trials have contributed considerably to our current understanding of specific interventions for heart failure and include: OPTIME HF (milrinone); REVIVE (levosimendan); VMAC, TRUE HF, and CD-NP (trials of natriuretic peptides including nesiritide, uleritide, and cenderitide in acute heart failure); EVEREST (tolvaptan) and a number of other trials of AVP antagonists; PROTECT (rolofylline); BEST (bucindolol), PRAISE II (amlodipine), A-HeFT (hydralazine/isosorbide mononitrate), SPICE and CHARM (candesartan). New devices often have great potential for clinical benefit, but research is needed to identify the proper patient population, indication, and combination with other standard therapies. I am interested in new technologies and how they can be used effectively in the clinical setting. I was the site PI for the first human application of renal denervation for the treatment of hypertension in North America. These first few procedures, performed in the cardiac catheterization laboratory at Hennepin County Medical Center, were instrumental in developing the protocol and techniques that would ultimately be used in the SIMPLICITY II and III studies. Another first in man experience based at HCMC in which I was the site PI was phrenic nerve stimulation as a means of treating central sleep apnea. These studies were critical in establishing proof of concept and developing pacing algorithms that were later incorporated into a fully implantible device that is currently under investigation. I was the site PI for the PEECH study examining the effectiveness and safety of enhanced external counterpulsation (EECP) in chronic heart failure and served on the Steering Committee and Writing Group for the International EECP patient registry which published papers examining the effect of EECP on peripheral arterial disease, erectile dysfunction, and severe 3 vessel coronary artery disease. I was invited to write a book chapter on the role of EECP in the management of chronic coronary artery disease. I have maintained an interest in nuclear cardiac imaging and have been the site PI for a number of related clinical trials. These trials have included studies of new vasodilator stress agents (regadenoson and other A2 selective adenosine agonists); ischemia markers such as iodofitic acid I123; imaging agents such as tetrofosmin; and an investigator initiated study comparing the accuracy of dobutamine stress echocardiography, dobutamine SPECT, and adenosine SPECT in patients with ESRD. 2 Other clinical trials I have participated in as site PI or Co-PI include studies of apixaban and otamixaban, new anticoagulants for acute coronary syndromes; growth factors for chronic ischemic heart disease (VEGF and FGF), carotid artery stiffness in patients at risk for CAD, antidepressants in post MI patients (SADHART), and the combination of PDE-5 inhibitors and IV nitroglycerin in patients with chronic coronary artery disease. My scholarly interests have led to publications and/or national presentations in the areas of underuse of ACE inhibitors (Am Journal of Cardiology 1997); ischemic versus non-ischemic cardiomyopathy (JACC 1997); the effects of cocaine on the formation of coronary artery aneurisms (Circulation 2005); long term survival in patients with chronic coronary artery disease (European Heart Journal 2013); and rare complications following septal reduction surgery in hypertrophic cardiomyopathy (Echocardiography 2013). c. Grants and contract support, peer-reviewed publications, non-peer reviewed publications, book chapters, scientific/professional presentations and abstracts Grants and Contracts Current Funding: Direct involvement as PI or Co-PI in 6 industry-sponsored clinical trials totaling more than $1.7 million for direct and indirect costs. Principal Investigator Current 1. Longitudinal Assessment of Cardiovascular and Renal Health in Patients with HepatitisC (CARE-Hep C) Protocol Version/ Date: Version 3.0, Bristol‐Myers Squibb, $68,250, Principal Investigator, February 2014-January 2015. (Direct cost, total project period) 2. Renal and neural hormonal effects of tolvaptan and B. type natruretic peptide in patients with congestive heart failure HSR#13-3708, $132,200, Principal Investigator, August 2013-July 2014. (Direct cost, total project period) 3. The Targeting Acute Congestion with Tolvaptan In Congestive Heart Failure StudyTACTICS-HF, Principal Investigator, $41,000, December 2012-November 2013. (Direct cost, Total project period) 4. A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) Protocol for Phase 3b Study of CVT3146 (Regadenoson) EXERRT – EXErcise to Regadenoson in Recovery Trial, $1,264,000, Principal Investigator, September 2012-September 2014. (Direct cost, total project period) 5. Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure, GAMBRO, #1494, Principal Investigator, July 2012-Present. (Annual project period) 3 Past 1. Renal Optimization Strategies Evaluation in Acute Heart Failure: ROSE-AHF, Heart Failure Network, Principal Investigator, March 2011-Present. (Annual project period) 2. Randomized, Double-blind, TD Trial to Compare the Efficacy of Otamixaban with Unfractionated Heparin + Eptifibatide in Patients with Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy, Sanofi, 04629-XRP0673A, Principal Investigator, July 2010-July 2013. (Total project period) 3. Hyponatremia Registry, Otsuka, #04645, Principal Investigator, December 2010December 2012. (Total project period) 4. Renal Denervation in Patients with Refractory Hypertension Pilot Study, Ardian, HSR # 08 2915, Principal Investigator, May 2009-2011. (Total project period) 5. Renal Denervation in End Stage Renal Disease Patients with Refractory Hypertension, Pilot Study, Ardian, HSR # 08 2916, Principal Investigator, May 2009-2011. (Total project period) 6. Comparative Effects of Conivaptan and Loop Diuretics on Plasma Neurohormones and Systemic and Renal Hemodynamics in Subjects with Chronic Heart Failure-CONVERT, Astelles, HSR # 09-3035, Principal Investigator, May 2009-2010. (Total project period) 7. Phase 4, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects with Renal Impairment-Lexiscan, Astellas, HSR #093089, Principal Investigator, August 2009-2010. (Total project period) 8. Appraise II: Apixaban for Prevention of Acute Ischemic Events – 2 A Phase 3, Randomized, Double-blind Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome, Bristol-Myers Squibb Research and Development, HSR # 09-3050, Principal Investigator, May 2009-2011. (Total project period) 9. Placebo-controlled, Randomized Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized with Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT), Merck, HSR#06-2693, Principal Investigator, 2006-2009. (Total project period) 10. Feasibility Study to Determine the Effects of Synchronized Phrenic Nerve Stimulation in Patients with Periodic Breathing, Cardiac Concepts, Inc., HSR#07-2841, Principal Investigator, $155,000, September 2007. (Direct cost, total project period) 11. Cardiorenal Rescue Study in Acute Decompensated Heart Failure-CARRESS, NIH HF Network, HSR#07-2862, Principal Investigator, April 2007. (Total project period) 4 12. Open-Label, Phase 2 Study of the Safety and Efficacy of -Methyl-p-[123l]-IodophenylPentadecanoic Acid (Iodofiltic Acid l 123) for Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Adults with Symptoms Consistent with Acute Coronary Syndrome (ACS), Molecular Insight Pharmaceuticals, Inc., HSR#07-2829, Principal Investigator (Percent effort: 2%), September 2007-September 2009. (Total project period) 13. Outpatient Ultrafiltration Therapy in Heart Failure – Pilot, CHF Solutions, Inc., HSR #06-2642, Principal Investigator, (Percent effort: 2%), $11,036, May 2006. (Total project period) 14. Phase 3, Parallel, Double-blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection with BMS068645 and Adenosine Stress Single Photon Emission Computer Tomography (SPECT) Compared to Coronary Angiography, BMS Medical Imaging, HSR#05-2497, Principal Investigator, (Percent effort: 2%), $138,000, 2005. (Direct cost, total project period) 15. Randomized, Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Cooling Techniques versus the Medivance Arctic Sun System, Medivance, HSR#04-2421, Principal Investigator, (Percent effort: 2%), $50,800, 2004. (Direct cost, total project period) 16. The UNLOAD Trial. Ultrafiltration versus IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure: A Prospective, Randomized Clinical Trial, CHF Solutions, Inc., HSR# 04-2377, Principal Investigator, (Percent effort: 2%), $52,500, 2004. (Direct cost, total project period) 17. Referral Bias in the Selection of Stress Echo and Myocardial Perfusion Imaging Studies, Investigator initiated and funded, HSR#04-2370, Principal Investigator, (Percent effort: 2%), 2004. (Total project period) 18. Phase II, Open-label, Randomized, Dose-selection, Multicenter Crossover Trial of BMS068645 in Subjects Undergoing Pharmacologic Stress Myocardial SPECT Imaging, Bristol Meyers Squibb, HSR# 04-2351, Principal Investigator, (Percent effort: 2%), $35,000, 2004. (Direct cost, total project period) 19. Non-invasive Measurement of Carotid Arterial Stiffness in Patients Admitted to a Short Stay Coronary Unit Using the Stiffness Index , Investigator initiated and funded, HSR# 04-2309, Principal Investigator, (Percent effort: 2%), 2004. (Total project period) 20. Exercised SPECT Myocardial Perfusion Imaging in Patients Receiving Beta-blockers: Impact of Adjuvant Adenosine Infusion on the Detection of Ischemia: BEAST-2, Fujisawa, HSR# 03-2299, Principal Investigator, $12,500, 2004. (Direct cost, total project period) 5 21. Study of Clinical Observations and Outcomes Following a Pharmacological Stress SPECT Myocardial Perfusion Imaging Procedure (Protocol #K627-02-5001), King Pharmaceuticals, #03-2166, Principal Investigator, February 2003-July 2003. (Total project period) 22. Enhanced Eternal Counterpulsation (EECP) in Heart Failure: A Single-blind, Controlled, Randomized Evaluation of Efficacy and Safety (PEECH), Vasomedical, #03-2210, Principal Investigator, (Percent effort:4%), $35,000, 2003. (Direct cost, total project period) 23. Randomized, Controlled Trial of Ultrafiltration for Decompensated Congestive Heart Failure, CHF Solutions, HSR# 03-2184, Principal Investigator, Multicenter Study, (Percent effort: 8%), $240,000, 2003. (Direct cost, total project period) 24. Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy versus Placebo in the Short-term Treatment of Decompensated Chronic Heart Failure (REVIVE), Orion Pharma, HSR# 02-1087, Principal Investigator, (Percent effort: 4%), $78,150, 2002. (Direct cost, total project period) 25. Effect of Enhanced External Counterpulsation (EECP) on Heart Rate Variability in Patients with Chronic Stable Angina, Vasomedical, HSR# 02-2059, (Percent effort: 2%), $5,000, 2002. (Direct cost, total project period) 26. The International Enhanced External Counterpulsation (EECP) Patient Registry (IEPR2), Vasomedical, HSR# 02-2011, Principal Investigator, (Percent effort: 1%), 2002. (Total project period) 27. Study of Clinical Observations and Outcomes Following a Pharmacological Stress SPECT Myocardial Perfusion Imaging Procedure, King Pharmaceutical Research and Development, Incorporated, HSR# 03-2166, Principal Investigator, (Percent effort: 2%), $7,500, 2002. (Direct cost, total project period) 28. International EECP Patient Registry 2 Men’s Health Study, Vasomedical, HSR# 022058, Principal Investigator, (Percent effort: 1%), 2002. (Total project period) 29. Double-blind, Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Highest Intravenous Dose of GTN That can Be Safely Administered in Men with Coronary Artery Disease Around Peak Systemic Exposure of Sildenafil, as Well as Safety and Tolerability of Intravenous GTN Given After a Single 100mg Dose of Sildenafil, Pfizer, HSR# 01-1032, Principal Investigator, (Percent effort: 1%), 2001. (Total project period) 30. P-Selectin Glycoprotein Ligand – LG Study, Wyeth-Ayerst Res, Principal Investigator, 2001. (Total project period) 6 31. Hennepin County Medical Center EEEP Patient Registry (HEPR), Investigator initiated and funded, HSR# 01-1051, Principal Investigator, (Percent effort: 1%), 2001. (Total project period) 32. The International Enhanced External Counterpulsation (EECP) Patient Registry (IEPR), Vasomedical, HSR# 01-948, Principal Investigator, (Percent effort: 1%), 2001. (Total project period) 33. Clinical Protocol for the Evaluation of the Cobalt Binding Test for Use as an Aid in the Diagnosis of Ischemia, Ischemia Technologies, Incorporated, HSR# 01-1059, Principal Investigator, (Percent effort: 2%), $45,000, 2001. (Direct cost, total project period) 34. Effect of Enhanced External Counterpulsation (EECP) on Heart Rate Variability and Baroreflex Sensitivity in Cardiac Patients, Investigator initiated and funded, HSR# 01982, Principal Investigator, (Percent effort: 1%), 2001. (Total project period) 35. Omipatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE), BristolMyers Squibb Davita, HSR# 00-911, Principal Investigator, (Percent effort: 2%), 2000. (Total project period) 36. Tc99m Gated SPECT Perfusion Imaging and Dobutamine Stress Echocardiography for the Evaluation of CAD and Prognosis in Renal Failure Patients, Hennepin Faculty Associates (HFA), HSR#99-749, Principal Investigator. 1999. (Total project period) 37. Tc99 Gated SPECT Perfusion Imaging and Dobutamine Stress Echocardiography for the Evaluation of Coronary Artery Disease and Prognosis in Renal Failure Patients, Minneapolis Medical Research Foundation (MMRF); DuPont Pharmaceuticals, HSR# 99-749, Principal Investigator, (Percent effort: 4%), $57,299 – MMRF; $7,500 – DuPont Pharmaceuticals, 1999. (Direct cost, total project period) 38. Bracco Tc 99m Teboroxime Run-in Study: A Clinical Evaluation to Determine Optimal Imaging Parameters for Tc-99m Teboroxime in Subjects with Coronary Artery Disease and Subjects with no Evidence of Coronary Artery Disease, Bracco Diagnostics, #99795, Principal Investigator, (Percent effort: 2%), 1999. (Total project period) 39. Candesartan Cilexetil (Candesartan) in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM), AstraZeneca Pharmaceuticals, HSR# 99-699, (Percent effort: 4%), $49,850, 1999. (Direct cost, total project period) 40. 12-week, Double-blind, Placebo-controlled, Multicenter Study of Oral YM087 to Assess Functional Capacity in Patients with Class III Chronic Heart Failure, ParkeDavis/Warner-Lambert Company, #98-596, Principal Investigator, (Percent effort: 4%), $28,000, 1998. (Direct cost, total project period) 41. Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of Intravenous Milrinone Versus Placebo in Reducing the Number of Days of 7 Hospitalization in the 60 Days Following Entry into the Study for Treatment of Leftsided Heart Failure (OPTIME of CHF), Sanofi Pharmaceuticals through Duke Clinical Research Institute, HSR# 97-464, Principal Investigator, (Percent effort: 2%), $15,000, 1997. (Direct cost, total project period) 42. Randomized, Double-blind, Placebo-controlled Trial of Sertraline (Zoloft) for Major Depression after Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina: The SADHART Trial, Pfizer through Duke Clinical Research Foundation, #97-463, Principal Investigator, (Percent effort: 4%), $36,407, 1997. (Direct cost, total project period) Co-Principal Investigator Current 1. TRUE HF Phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety ularitide intravenous infusion in patients suffering from acute decompensated heart failure, $259,060, Co-Principal Investigator, March 2013–Present, (Total cost, annual project period) Past 1. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients: EXACT-HF, Heart Failure Network, Co-Principal Investigator, 2010-Present. (Total project period) 2. Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency – TRIDENT, Biogen, HSR # 09-3038, CoPrincipal Investigator, June 2009-2010. (Total project period) 3. Multi-Center, Randomized, Placebo-controlled, Phase 2B Study Assessing the Safety and Efficacy of Early Administration of Intravenous CD-NP Versus Placebo in the Treatment of Patients with Acute Decompensated Heart Failure – CONDITION, Nile, HSR# 093026, Co-Principal Investigator, April 2009-2010. (Total project period) 4. Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients with Decompensated Chronic Heart Failure, Yamanouchi Pharma America, Inc., HSR# 02-2097, Co-Principal Investigator, (Percent effort: 2%), 2003. (Total project period) 5. The African American Heart Failure Trial (A-HeFT) a Placebo-controlled Trial of BiDil Added to Standard Therapy in African American Patients with Heart Failure and Substudy – Genetic Risk Assessment of Heart Failure in African Americans (GRAHF), Nitromed, Inc., HSR# 01-1035, Co-Principal Investigator, (Percent effort: 2%), 2003. (Total project period) 6. Multicenter, Randomized, Double-blind, Placebo-controlled Study of OPC-41061 to Evaluate the Effects of OPC-41061 on the Acute and Chronic Outcomes of Patients Hospitalized with Worsening Congestive Heart Failure, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV-CHF), Otsuka 8 America Pharmaceuticals, Inc., HSR# 00-926, Co-Principal Investigator, (Percent effort: 2%), 2001. (Total project period) 7. Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Evaluate the Efficacy and Safety of Ad.1 FGF-4 in Patients with Stable Angina, Berlex Labs, Inc., #01-997, Co-Principal Investigator, (Percent effort: 2%), 2001. (Total project period) 8. Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic and Clinical Effects of Natrecor (nesiritide) Compared with Nitroglycerin Therapy for Symptomatic Decompensated CHF, Scios, #99-769, Co-Principal Investigator, (Percent effort: 2%), 2000. (Total project period) 9. Randomized, Double-blind Study to Compare the Effects of Carvedilol versus Placebo on Left Ventricular Remodeling in Patients Post-myocardial Infarction (COVERT), Glaxo Smith Kline, #98-634, Co-Principal Investigator, (Percent effort: 2%), 2000. (Total project period) 10. Multicenter, Open-label, Dose-escalating Study of Intramyocardial Vascular Endothelial Growth Factor 2 (VEGF 2) Gene Therapy in Refractory Patients with Stable Exertional Angina who are no Candidates for Revascularization Procedures, Genetech, #99-682, CoPrincipal Investigator, (Percent effort: 2%), 1999. (Total project period) 11. Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), BristolMyers Squibb, #99-770, Co-Principal Investigator, (Percent effort: 2%), 1999. (Total project period) 12. Phase II, Double-blind, Placebo-controlled Study to Assess the Effect of Intracoronary and Multiple Intravenous Administrations of rh VEGf on Exercise Tolerance in Adults with Viable but Underperfused Myocardium (VIVA VEGf), Genentech, Co-Principal Investigator, (Percent effort: 2%), 1997. (Total project period) 13. The Effect of Amlodipine on Regional Myocardial Blood Flow in Patients with Ischemic Cardiomyopathy, Pfizer, Co-Principal Investigator, (Percent effort: 5%), $15,000, 1996. (Direct cost, total project period) 14. The Effect of Amlodipine on Regional Myocardial Blood Flow using Dynamic Positron Emission Tomography in Patients with Non-ischemic Cardiomyopathy, Pfizer, CoPrincipal Investigator for the PRAISE II sub-study, (Percent effort: 5%), $15,000, 1996. (Direct cost, total project period) Co-investigator Past 1. CardioMems Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients-CHAMPION, CardioMems, Co-Investigator, July 2007. (Total project period) 9 2. Phosphodiesterase-5 Inhibition to Improve Quality of Life and Exercise Capacity in Diastolic Heart Failure – RELAX, NIH HF Network, HSR#07-2851, Co-Investigator, April 2007. (Total project period) 3. Diuretic Optimization Strategies Evaluation in Acute Heart Failure-DOSE, NIH HF Network, HSR#07-2852, Co-Investigator, April 2007. (Total project period) 4. NIH Heart Failure Network, NIH, #6099, Co-Investigator, (Percent effort: 20%), $900,000, September, 2006 – September, 2011. (Direct cost, total project period) 5. Phase II, Multi-Center, Randomized, Double-blind, Flexible-dose Study of ZP120 Administered with IV Infusion as Add-On Therapy in Patients with Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated with Furosemide (Zealand), Zealand, HSR#06-2627, Co-Investigator, 2006-2007. (Total project period) 6. 12-week, Randomized, Open-label, 3-arm, Parallel-group Multicenter, Phase 111b Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 in Patients with Acute Coronary Syndromes (LUNAR), Astra/Zeneca, HSR#06-2598, Co-Investigator, 2006-2007. (Total project period) 7. Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Longterm Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure, Otsuka, #03-2271, Co-Investigator, (Percent effort: 1%), 2003. (Total project period) 8. Exploratory Study of Intravenously Administered YM 087 (CI-1025) to Assess Safety and Efficacy in Patients with Acute Decompensation of Chronic Heart Failure, ParkeDavis/Warner-Lambert Company, #99-797, Co-Investigator, (Percent effort: 1%), 1997. (Total project period) Investigator Past 1. Randomized, Double-blind, Multicenter Pilot Safety Study of the Addition of Ecadotril 50 to 400 mg BID or Placebo to the Background of Conventional Therapy in Patients with Symptomatic Congestive Heart Failure, Bayer, #Bay y 7432, Investigator, (Percent effort: 4%), 1996. (Total project period) 2. PRAISE II, Phase III trial of Amlodipine in Patients with Nonischemic Cardiomyopathy, Pfizer, Investigator, (Percent effort: 2%), 1996. (Total project period) 3. BEST Phase III Trial of Bucindolol in Patients with CHF, US National Heart, Lung, and Blood Institute; Department of Veterans Affairs Cooperative Studies Program; Incara Pharmaceuticals (drugs), Investigator, (Percent effort: 2%), 1996. (Total project period) 10 Peer-reviewed publications Citation Indices accessed May, 2014 by Google Scholar, Citations 2567; h-index 20; 10-index 25 1. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network.. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure with Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA. 2013; 310(23):2533-2543. doi:10.1001/jama.2013.282190. Contribution: Developed protocol with Heart Failure Network Steering Committee, site investigator, enrolled patients, assisted in review of data and analysis, assisted in review and editing of manuscript. Impact Factor: 29.978 in 2012; Sum of times cited: 13 2. Schlaich MP, Bart BA, Hering D, Walton A, Marusic P, Mahfoud F, Bohm M, Lambert EA, Krum H, Sobotka PA, Schmieder RE, Ika-Sari C, Eikelis N, Straznicky N, Lambert GW, Esler MD. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214-2220. Contribution: Assisted in protocol development, site principal investigator, enrolled patients, assisted in review of data and analysis, assisted in review and editing of manuscript Impact Factor: 5.509 in 2012; Sum of times cited: 29 3. Chen HH, AbouEzzeddine OF, Anstrom KJ, Givertz MM, Bart BA, Felker GM, Hernandez AF, Lee KL, Braunwald E, Redfield MM; Heart Failure Clinical Research Network. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ Heart Fail. 2013;6(5):1087-1094. Contribution: developed protocol with Heart Failure Network Steering Committee, site investigator, enrolled patients, assisted in review of data and analysis, assisted in review and editing of manuscript. Impact Factor: 6.684 in 2012; Sum of times cited: 1 4. Kalra A, Kohl LP, Asinger RW, Bachour FA, Van Camp JR, Ayenew W, Bart BA. Aorto-right atrial fistula at aortotomy site following surgical myectomy. Echocardiography. 2013;30(9):E300-301. Contribution: Initially described the case and assisted with review and editing of manuscript. Impact Factor: 1.261 in 2012; Sum of times cited: 1 5. Bart BA, Nelson SE. Eplerenone: another drug to add to the mix? J Am Coll Cardiol. 2013;62(17):1594-1595. 11 Contribution: Invited to write this editorial, assisted with review and editing of manuscript. Impact Factor: 14.086 in 2012; Sum of times cited: 1 6. Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, et al. Long-term survival in patients with refractory angina. Eur Heart J. Published online May 12, 2013; doi:10.1093/eurheartj/eht165. Contribution: Patient recruitment and enrollment for participation in the registry, assisted with review and editing of manuscript. Impact Factor: 14.097 in 2012; Sum of times cited: 4 7. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, et al. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial (RELAX trial). JAMA. 2013;309(12):1268-1277. Contribution: developed protocol with Heart Failure Network Steering Committee, site investigator, enrolled patients, assisted in review of data and analysis, assisted in review and editing of manuscript. Impact Factor: 29.978 in 2012; Sum of times cited: 80 8. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304 Contribution: Developed and wrote protocol with Heart Failure Network Steering Committee, national principal investigator, enrolled patients, primary review of data and analysis, wrote manuscript. Impact Factor: 51.658 in 2012; Sum of times cited: 139 9. Bart BA, Goldsmith SR, Lee KL, et al. Cardiorenal rescue study in acute decompensated heart failure: Rationale and design of CARRESS-HF, for the heart failure clinical research network. J Card Fail. 2012;18(3):176-182. Contribution: Developed and wrote protocol with Heart Failure Network Steering Committee, national principal investigator, wrote manuscript. Impact Factor: 3.320 in 2012; Sum of times cited: 32 10. Ponikowski P, Javaheri S, Michalkiewicz D, Bart B, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J. 2012;33(7):889-894. Contribution: Site principal investigator of this first-in-man device feasibility trial, helped develop the study protocol, enrolled patients, oversaw procedure and testing, assisted in editing of manuscript. Impact Factor: 14.097 in 2012; Sum of times cited: 36 11. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, 12 Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. Contribution: Developed protocol with Heart Failure Network Steering Committee, site investigator, enrolled patients, assisted in review of data and analysis, assisted in review and editing of manuscript. Impact Factor: 51.658 in 2012; Sum of times cited: 343 12. Goldsmith SR, Sobotka PA, Bart B. The sympathorenal axis in hypertension and heart failure. J Card Fail. 2010;16(5):369-373. Contribution: developed concept, assisted in writing and editing of manuscript. Impact Factor: 3.320 in 2012; Sum of times cited: 5 13. Thakkar BV, Hirsch AT, Satran D, Bart BA, et al. The efficacy and safety of enhanced external counterpulsation in patients with peripheral arterial disease. Vasc Med. 2010;15(1):15-20. Contribution: Patient recruitment and enrollment for participation in the registry, assisted with review and editing of manuscript. Impact Factor: 1.617 in 2012; Sum of times cited: 5 14. Shroff GR, Cen YY, Duprez DA, Bart BA. Relationship between carotid artery stiffness index, BNP and high-sensitivity CRP. J Hum Hypertens. 2009;23(12):783-787. Contribution: Resident research advisor, assisted in development of protocol, review and analysis of data, review and editing of manuscript. Impact Factor: 2.818 in 2012; Sum of times cited: 5 15. Bart BA. reatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail. 2009;2(5):499-504. Contribution: Invited perspective piece, wrote manuscript. Impact Factor: 6.684 in 2012; Sum of times cited: 32 16. Bart BA, Cen YY, Hendel RC, et al. Comparison of dobutamine stress echocardiography, dobutamine SPECT, and adenosine SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2009;16(4):507-515. Contribution: Principal investigator of this investigator-initiated project, independently developed the concept and study design, wrote study protocol, responsible for conduct of study, data acquisition, analysis and manuscript preparation. Impact Factor: 2.847 in 2012; Sum of times cited: 7 17. Thorsgard M, Bart BA. Ultrafiltration for congestive heart failure. Congest Heart Fail. 2009;15(3)136-143. Contribution: Developed the overall organization of the review, provided key references, wrote significant portions of the text in collaboration with the co- author. Impact Factor: Information not available; Sum of times cited: 1 13 18. Campbell AR, Satran D, Zenovich AG, Campbell KM, Espel JC, Arndt TL, Poulose AK, Boisjolie CR, Juusola K, Bart BA, Henry TD. Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. Am Heart J. 2008;156(6):1217-1222. Contribution: Patient recruitment and enrollment for participation in the registry, assisted with review and editing of manuscript. Impact Factor: 4.497 in 2012; Sum of times cited: 17 19. Bart BA, Walsh MM, Blake D, Goldsmith SR. Ultrafiltration for cardiorenal syndrome. J Card Fail. 2008;14(6):531-532. Contribution: Study design and concept, intellectual content, database development, statistical analysis, manuscript preparation. Impact Factor: 3.320 in 2012; Sum of times cited: 9 20. Parker JD, Bart BA, Webb DJ, et al. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med. 2007;35:1863-1868. Contribution: Assisted in cortical development, site principal investigator, screamed and enrolled patients, personally supervised administration of study drug, review and analysis of data, review and editing of manuscript. Impact Factor: 6.124 in 2012; Sum of times cited: 15 21. Michaels AD, Bart BA, Pinto T, et al. The effects of enhanced external counterpulsation on time- and frequency-domain measures of heart rate variability. J Electrocardiol. 2007;40 (6):515-521. Contribution: Principal investigator; developed concept and study design for multicenter, investigation–initiated trial; manuscript writing, editing and review. Impact Factor: 1.093 in 2012; Sum of times cited: 7 22. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675-683. Contribution: Study and protocol development design, intellectual content and concepts, data analysis, manuscript writing, editing and review. Impact Factor: 14.086 in 2012; Sum of times cited: 598 23. Soran O, Kennard ED, Bart BA, Kelsey SF for the IEPR Investigators. Impact of external counterpulsation treatment on emergency department visits and hospitalizations in refractory angina patients with left ventricular dysfunction. Cong Heart Fail. 2007;13(1):36-40. Contribution: Planning for and creating registry database as part of IEPR working group, intellectual content, manuscript editing and review. Impact Factor: Information not available; Sum of times cited: 21 24. Bart BA. Ultrafiltration for heart failure. Cardiol Rev. 2006;23(7):16-19. Impact Factor: Information not available; Sum of times cited: Information not available. 14 25. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46(11):2043-2046. Contribution: Principal Investigator/Project Leader of this investigator-initiated multicenter project; produced study concept and design; wrote protocol; obtained funding; developed forms, procedures and database; selected and defined data elements; data analysis and manuscript preparation. Impact Factor: 14.086 in 2012; Sum of times cited: 248 26. Bart BA, Erlien DA, Herzog CA, Asinger RW. Marked differences between patients referred for stress echocardiography and myocardial perfusion imaging studies. Am Heart J. 2005;149(5):888-893. Contribution: Study design and concept, intellectual content, database development, statistical analysis, manuscript preparation. Impact Factor: 4.497 in 2012; Sum of times cited: 9 27. Satran A, Bart BA, Henry CR, et al. Increased prevalence of coronary artery aneurysms among cocaine users. Circulation. 2005;111(19):2424-2429. Contribution: Blinded review of angiograms, database development, review and editing of manuscript. Impact Factor: 15.202 in 2012; Sum of times cited: 64 28. Shah BR, Velazquez E, Shaw LK, Bart BA, O’Conner C, Wagner, GS. Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. Am Heart J. 2002;143(1):111-117. Contribution: Manuscript review and editing. Impact Factor: 4.497 in 2012; Sum of times cited: 4 29. Wellan DJ, Shaw LK, Bart BA, Kraus WE, Califf RM, O’Conner CM. Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction. Am Heart J. 2001;142(1):160-166. Contribution: Database development, manuscript review. Impact Factor: 4.497 in 2012; Sum of times cited: 20 30. Shah MR, Granger CB, Bart BA, et al. Sex-related differences in the use and effects of angiotensin-converting enzyme inhibitors in heart failure: the SPICE (study of patients intolerant of converting enzyme inhibitors) registry. Am J Med. 2000;109(6):489-492. Contribution: Review and editing of manuscript. Impact Factor: 4.768 in 2012; Sum of times cited: 28 31. Granger CCB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, WarnerStevenson L, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and 15 a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139(4):609-617. Contribution: Study design, wrote protocol, selected data elements and structured database, international coordination and training of international site investigators and monitors, international project coordinator (100 sites), review and editing of manuscript. Impact Factor: 4.497 in 2012; Sum of times cited: 103 32. Bart BA, Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance. Am Heart J. 1999;138(5) Pt 1:801-803. Contribution: Intellectual content and manuscript preparation. Impact Factor: 4.497 in 2012; Sum of times cited: 16 33. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. Eur Heart J. 1999;20(16):1182-1190. Contribution: Study design and concept; intellectual content; wrote protocol, developed forms and database with definition of data elements; international study coordination (100 sites) and training of investigators; manuscript preparation. Impact Factor: 14.097 in 2012; Sum of times cited: 125 34. Bart BA, Goldsmith SG. Aggravated renal dysfunction and the acute management of advanced chronic heart failure. Am Heart J. 1999(2) Pt 1;138:200-202. Contribution: Intellectual content and manuscript preparation. Impact Factor: 4.497 in 2012; Sum of times cited: 16 35. Shah BR, Lin C, Maynard C, Bart BA, et al. Specificity of electrocardiographic myocardial infarction screening criteria in patients with nonischemic cardiomyopathies. Am Heart J. 1998;136(2):314-319. Contribution: Study design, intellectual content and concept, manuscript editing and review. Impact Factor: 4.497 in 2012; Sum of times cited: 2 36. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O’Connor CM. Is optimal ACE-inhibitor dosing neglected in elderly heart failure patients? Am Heart J. 1998;136(1):43-48. Contribution: Manuscript editing and review. Impact Factor: 4.497 in 2012; Sum of times cited: 54 37. Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30(4):1002-1008. Contribution: Principal investigator, independently developed the concept and study design, responsible for conduct of the study, data acquisition, analysis, manuscript preparation. Impact Factor: 14.086 in 2012; Sum of times cited: 263 16 38. Bart BA, Gattis WA, Diem SJ, O’Connor CM. Reasons for underuse of angiotensinconverting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J of Cardiol. 1997;79(8):1118-1120. Contribution: Principal Investigator, independently developed the concept and study design, responsible for conduct of the study, data acquisition and analysis, manuscript preparation. Impact Factor: 3.209 in 2012; Sum of times cited: 91 39. Melvin D, Shah BR, Maynard C, Bart BA, Wagner GS. Left ventricular hypertrophy impairs detection of myocardial infarction in patients with nonischemic cardiomyopathy. North Carolina Med J. 1997;58(2):134-137. Contribution: Database design and development, intellectual content of manuscript, review and editing of manuscript. Impact Factor: Information not available; Sum of times cited: 6 40. Bart BA, Wolfel EE. Method of expired gas collection during cardiopulmonary exercise testing does not affect respiratory gas exchange measurements in patients with heart failure. J Card Failure. 1994;1(1):91-96. Contribution: Principal Investigator of this investigator-initiated project, independently developed the concept and study design, wrote study protocol, responsible for conduct of study, data acquisition, analysis and manuscript preparation. Impact Factor: 3.320 in 2012; Sum of times cited: 1 Peer-reviewed publications, accepted for publication 1. Goldsmith SR, Bart BA, Burnett JC. Decongestive therapy and renal function in acute heart failure: Time for a new approach? Circ Heart Fail. Accepted for publication, April 2014. Non peer-reviewed publications 1. Bart BA, Hernandez AF. Ultrafiltration in Heart Failure with Cardiorenal Syndrome. N Engl J Med. 2013;368(12):1159-60 2. Bart BA. Book review. The cardiorenal syndrome: a clinician’s guide to pathophysiology and management. Circulation. 2012;126. 3. Bart BA, Goldsmith SR, Boyle A, Costanzo MR. Renal function and ultrafiltration. J Card Fail. 2008;14(6):533-534. Contribution: Intellectual content and writing of manuscript. 4. Bart BA. Advances in Heart Failure, Minnesota’s Role in the NHLBI’s Heart Failure Network. Minn Med. 2008;40-42. 5. Bart BA. Heart failure. New treatments can help manage the disease. Minnesota Healthcare News. 2007;5(6):16-17. 6. Bart BA. Clinical Tips. IEPR Newsletter. 2005;7(2):5. 17 7. Bart BA. Quality of life for patients with congestive heart failure. IEPR Newsletter. 2004:6(2):1. 8. Juusola K, Sigafus M, Smyrak L, Bart BA. IEPR Site Spotlight: Hennepin County Medical Center. IEPR Newsletter. 2004;6(3):4. Contribution: Intellectual content, review and editing of manuscript. 9. Fenstad ER, Boisjolie CR, Henry TD, Bart BA. EECP: an option for "no option" cardiac patients. Minnesota Physician. 2001;XV(2). Contribution: Intellectual content, review and editing of manuscript. 10. Bart BA, O’Connor CM. Clinical determinants of mortality in patients with cardiomyopathy. Cardiology Review. 1999;16:9-11. Contribution: Intellectual content and writing of manuscript. 11. Bart BA, Eisenberg PR. Clinical case studies in heart failure. Edited by O’Connor CM. New York, Pfizer, April, 1996. Contribution: Intellectual content and writing of manuscript. 12. Bart BA. Maximal work capacity elicited by treadmill and ski ergometry in wellconditioned male and female cross-country skiers. Master of Science Thesis. Department of Physiology, University of Minnesota, Minneapolis, Minnesota, 1989. Contribution: Wrote protocol, screened and enrolled participants, personally present during all testing, acquired, reviewed, and analyzed data, wrote thesis. Book Chapters 1. Bart BA. Ultrafiltration for the management of volume overload. In: Semigran MJ, Shin JT, eds. Heart Failure, Second Edition. Boca Raton, Florida: Taylor & Francis Group; 2013:427-444. Contribution: Intellectual content and manuscript preparation. 2. Bart BA. Enhanced External Counterpulsation. In: Barsness GW, Holmes DR, eds. Coronary Artery Disease: New Approaches without Traditional Revascularization. London, England: Springer; 2012:53-66. Contribution: Intellectual content and manuscript preparation. 3. Bart BA, Goldsmith SR. Other Neurohormonal Systems. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure, 3rd edition. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2006:193-204. Contribution: Intellectual content and manuscript preparation. 18 Presentations Invited Oral Presentations at International Professional Meetings, Conferences 1. “The Use of Ultrafiltration for the Management of Acute Heart Failure,” International Renal Replacement Therapy Meeting, Bellvitge Hospital, Barcelona, Spain, October 11, 2013. Invited Oral Presentations at National Professional Meetings, Conferences 1. “Effect of heart failure treatment strategies on development of cardiorenal syndrome," 63rd annual scientific sessions of the American College of Cardiology, Washington DC, 2014. 2. "Rule of ultrafiltration in acute decompensated heart failure," joint symposium of the German Cardiac Society and Thai Heart Association and the American College of Cardiology, 63rd Annual Scientific Sessions of the American College of Cardiology, Washington, DC, 2014. 3. “Heart Failure Trials: The Year in Review,” CARRESS-HF 17th Annual Scientific Meeting, Heart Failure Society of America, Orlando, Florida, September 23, 2013. 4. “Advantages and Pitfalls of Ultrafiltration Therapy,” American College of Cardiology’s 61st Annual Scientific Sessions and Expo, Chicago, Illinois, March 25, 2012. 5. “Hemoconcentration with Ultrafiltration: Good or Bad?” 15th Annual Scientific Meeting, Heart Failure Society of America, Boston, Massachusetts, September 19, 2011. 6. “Management of Acute Fluid Overload: Diuretics vs. Aquaphoresis,” Transcatheter Cardiovascular Therapeutics (TCT) Meeting, Washington, DC, 2007. 7. “Ultrafiltration Benefits and Mechanisms,” Heart Failure Society of America, 11th Annual Scientific Meeting, Washington, DC, 2007. 8. “Heart Failure for the Consultant Cardiologist: 2007 Update,” Session Co-chair, 56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 2007. 9. “Meet the Thought Leaders and Industry Experts on EECP Therapy: A Noninvasive Therapy for Heart Failure and Angina Pectoris," Meet the Experts, American College of Cardiology, Satellite Symposia, Orlando, Florida, 2005. 10. “Therapeutic Ultrafiltration for the Management of Fluid Overload: Current and Future Role–The RAPID CHF Study,” Satellite Symposium, Heart Failure Society of America, Las Vegas, Nevada, 2003. 11. “CAD in Women,” Top Guns of the Future, Disney Institute, Orlando, Florida, 2001. 19 12. “CAD vs. Non-CAD,” Heart Failure Society of America, 2nd Scientific Meeting, Boca Raton, Florida, 1998. 13. “Management of Heart Failure,” Panelist, 15th Edward S. Orgain Cardiovascular Symposium, Durham, North Carolina, 1996. 14. “Managing CHF: Staying beyond the Hospital Walls,” Facilitator, Heart Center Conference, Roundtable Discussion, Durham, North Carolina, 1995. Invited Oral Presentations at Local and Regional Professional Meetings, Conferences 1. “Hot Topics from the American College of Cardiology (ACC) 2014,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, April 24, 2014. 2. “Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome–The Creation of a Comparative Effectiveness Trial,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, December 6, 2012. 3. “Cardiorenal Syndrome: CARRESS HF Trial Results and Implications,” Heart Failure 2012: The Update, Minnesota Heart Failure Consortium, Edina, Minnesota, December 1, 2012. 4. “Hypertension Panel,” Panelist, Heartland Summit, Piper Jaffray Headquarters, Minneapolis, Minnesota, August 16, 2012. 5. “Heart Failure and Renal Failure,” Heart Failure 2011: The Update, 9th Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota, October 29, 2011. 6. “NHLBI Heart Failure Clinical Trials Network–Introduction to Selected Ongoing Trials at Hennepin County Medical Center,” Geriatrics Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, August 9, 2011. 7. “Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010. 8. “Should All Patients with Decompensated Heart Failure and Volume Overload Receive Ultrafiltration?” Debate, Pro: Bart BA, Con: Walsh M. Heart Failure 2009: The Update, 7th Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota, November 7, 2009. 9. “Renal Denervation for Hypertension,” Clinical Nephrology Conference, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, January 9, 2009. 10. “Wanted: Dead or Alive; Myocardial Viability Testing,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, December 11, 2008. 20 11. “Changes in Renal Function during Heart Failure Therapy: What is the Kidney Trying to Tell Us?” 30th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota, December 4, 2008. 12. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Heart Institute, Minneapolis, Minnesota, November 24, 2008. 13. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Veterans Medical Center, Minneapolis, Minnesota, November 21, 2008. 14. “Future of Academic Cardiovascular Medicine,” Radisson Hotel, University of Minnesota, Minneapolis, Minnesota, September, 2008. 15. “Ultrafiltration for Heart Failure: Mechanisms and Benefits,” 29th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota, 2008. 16. “Ablation of Renal Sympathetic Nervous System Trial,” (Denervation Trial), Hennepin County Medical Center, Division of Nephrology, Minneapolis, Minnesota, 2007. 17. “The Stages of Heart Failure,” Mercy Medical Center, Coon Rapids, Minnesota, 2006. 18. “The Cardiologist’s Role in Heart Failure Stages A-D.” CME Program for Minnesota Chapter of the American College of Cardiology Annual Meeting, Minneapolis, Minnesota, 2006. 19. “Do All Patients with an EF <35% Need an ICD Device?” Debate Speaker, Pro: Alan Bank, Con: Bart BA, Heart Failure 2006: The Update, Bloomington, Minnesota, 2006. 20. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” CHF Solutions, Inc., Brooklyn Park, Minnesota, 2006. 21. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds, Saint Paul Heart Clinic, Saint Paul, Minnesota, 2006. 22. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand Rounds, University of Illinois, Chicago, Illinois, 2006. 23. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2006. 24. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds, Veterans Administration Medical Center, Minneapolis, Minnesota, 2006. 25. External Counterpulsation Therapy for Ischemic Heart Disease,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2005. 21 26. “Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2005. 27. “Ultrafiltration in the Postoperative and Congestive Heart Failure Patients," Cardiology/Surgery Conference, United Hospital, Saint Paul, Minnesota, 2005. 28. “Heart to Heart," Lunchtime Health Series with Hennepin County Medical Center, Hennepin Faculty Associates and Minneapolis Medical Research Foundation, Minneapolis, Minnesota, 2005. 29. “Assessment of Myocardial Viability,” Interventional Cardiology Conference, University of Minnesota, Minneapolis, Minnesota, 2005. 30. “Assessment of Myocardial Viability,” Health Partners 28th Annual Cardiovascular Conference, Saint Paul, Minnesota, 2005. 31. “Does this Patient with Nonischemic Cardiomyopathy Need a Defibrillator?" Cardiology Conference, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, 2004. 32. “Infarct Size and Myocardial Perfusion Imaging,” Possis, Inc. Sponsored Event, Minneapolis, Minnesota, 2004. 33. “Results of the RAPID Trial,” Investigators’ Meeting, Chicago, Illinois, 2004. 34. “Results of the RAPID Trial,” Investigators’ Meeting, Minneapolis, Minnesota, 2004. 35. “Update in Cardiology," East Minneapolis Downtown Council, Minneapolis, Minnesota, 2004. 36. “Should this Patient get a Defibrillator: Controversies in Cardiology," Scientific and Business Meeting, American College of Cardiology-Minnesota Chapter, Minneapolis, Minnesota, 2004. 37. “Current Therapies for Treating Inpatient CV Disease," Cardiology Noon Conference, Mercy and Unity Hospitals, Coon Rapids, Minnesota, 2004. 38. “Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. 39. “Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University of Minnesota, Minneapolis, Minnesota, 2004. 40. “Heart to Heart,” Lunchtime Health Series with Hennepin County Medical Center, Hennepin Faculty Associates and Minneapolis Medical Research Foundation, Minneapolis, Minnesota, 2004. 22 41. “Screening for Coronary Heart Disease,” Scientific Meeting, American College of Cardiology-Minnesota Chapter, Brooklyn Park, Minnesota, 2003. 42. Minnesota Medical Research Foundation Brown Bag Seminar Series, Hennepin County Government Center, Minneapolis, Minnesota, 2003. 43. “CAD Screening in the Asymptomatic Patient,” 11th Annual Family Practice Update, Hennepin County Medical Center, Minneapolis, Minnesota, 2002. 44. “External Counterpulsation for the Treatment of Angina Pectoris.” Cardiology Conference, North Memorial Heart Center, Minneapolis, Minnesota, 2002. 45. “External Counterpulsation for the Treatment of Angina Pectoris,” Research Conference, Fairview-University Medical Center, Minneapolis, Minnesota, 2002. 46. “Nuclear Cardiac Imaging and Risk Stratification: What You Need to Know,” DuPont Sponsored Program, Eau Claire, Wisconsin, 2001. 47. “Angiotensin Receptor Blockers and the RAAS: A Review and Discussion of Potential Uses in Cardiovascular Diseases,” Merck Sponsored Event, Rapid City, South Dakota, 2001. 48. “Risk Stratification in Women Using Nuclear Perfusion Imaging,” DuPont Sponsored Event, Merrillville, Indiana, 2001. 49. “CAD in Women,” Bristol-Myers Squibb Sponsored Event, Omaha, Nebraska, 2001. 50. “Risk Stratification and Prognosis of CAD in Special Patient Populations,” Bristol-Myers Squibb Sponsored Event, South Bend, Indiana, 2001. 51. Primacor National Advisory Council Dinner Meeting, Co-Chair, Sanofi-Synthelabo Sponsored Event, Minneapolis, Minnesota, 2001. 52. “Angiotensin Receptor Blockers–Mechanism of Action and New Applications,” Merck Sponsored Lecture, Eau Claire, Wisconsin, 2000. 53. “Nuclear Cardiology–Prognosis and Clinical Implications,” Wausau Hospital Cardiac Conference, Wausau, Wisconsin, 2000. 54. “Nuclear Cardiology from the Cardiologist’s Perspective,” Minnesota Radiological Society Fall Meeting, Minneapolis, Minnesota, 2000. 55. “Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 2000. 23 56. “Angiotensin Receptor Blockers: Mechanisms and New Directions,” Grand Rounds, Veterans Administration Medical Center, Minneapolis, Minnesota, 1998. 57. “Nuclear Cardiac Imaging,” Medicine Grand Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 1997. Peer-Reviewed Oral Abstract Presentations at Professional Meetings, Conferences 1. Parker JD, Bart BA, Webb D, Koren MJ, Siegel RL, Nicholas S. A double-blind, placebo-controlled, crossover study of the safety of intravenous glycerol trinitrate after administration of sildenafil citrate to men with coronary artery disease. American College of Cardiology, Scientific Sessions, Orlando, Florida, 2005. 2. Shroff GR, Herzog CA, Cen YY, Bart BA. Carotid stiffness index β significantly correlates with coronary heart disease risk score., American College of Cardiology, Scientific Sessions, San Francisco, California, 2005. 3. Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically proven ischemic and nonischemic cardiomyopathy., 69th Scientific Sessions of the American Heart Association, New Orleans, Louisiana, 1996. Circulation. 1996;94(8):I-193. 4. Bart BA, Wolfel EE, Bristow MR. The effect of the method of expired gas collection on respiratory gas exchange measurements in patients with heart failure., American College of Sports Medicine 40th Annual Meeting, Seattle, Washington, 1993. 5. Bart BA. Acute respiratory distress in an asthmatic following adenosine. Winner, American College of Physicians Associates Clinical Vignette Competition, , American College of Physicians Annual Meeting, San Diego, California, 1992. 6. Bart BA, Leon AS. Maximal oxygen uptake (VO2max) by ski ergometry in men and women collegiate champion cross-country skiers. American College of Sports Medicine 37th Annual Meeting, Salt Lake City, Utah, 1990. J Amer Coll Cardiol. 2001;37(2):7A. Poster Abstract Presentations at Professional Meetings, Conferences 1. Yannopoulos D, Mahoney B, Garcia S, Frascone R, Helmer G, Lick C, Conterato M, Baran K, Roh S, Panetta C, Stark R, Haughland M, Mooney M, Bart BA. Early access to cardiac catheterization laboratory for patients resuscitated from cardiac arrest due to a shockable rhythm. The Minnesota Resuscitation Consortium Twin Cities unified protocol. Circulation. 2013;128:A310. 2. Bart G, Bart BA, Karim R, Wyman Z. Methadone dose and the QTc interval: little clinical relevance, big unknowns. Abstract from the 73rd Annual Scientific Meeting, College on Problems of Drug Dependence, Hollywood, Florida, 2011. 24 3. Augostini RS, Jagielski D, Ponikowski P, Oldenburg O, Gutleben KJ, Michalkiewicz D, Karim R, Bart BA, et al. Phrenic nerve stimulation for central sleep apnea in congestive heart failure does not interfere with the functioning of existing implantable cardiac devices. Heart Rhythm. 2011;8(5)Suppl1:S61. 4. Ahmed I, Bart G, Bart BA. Cocaine users hospitalized for acute decompensated heart failure: falling between the cracks-an opportunity for improved care. J Card Fail. 2010;16(8):S109. 5. Abraham WT, Zhang SJ, Michalkiewicz D, Hasan A, Bart BA, et al. Results of chronic phrenic nerve stimulation using the RespiCardia™ System are comparable to acute results in the improvement of central sleep apnea. First-inMan Experience, American Heart Association Resuscitation Science Symposium, Chicago, Illinois, November 2010. 6. Mulder M, Scott NL, Bart BA, Sprenkle M, Bachour F, Smith SW. Early post resuscitative care of adult, non-traumatic cardiopulmonary arrests is rarely affected by routine head computed tomography. American Heart Association Resuscitation Science Symposium, Chicago, Illinois, November 2010. 7. Ponikowski P, Witkowski T, Khayat R, Michalkiewicz D, Bart BA, Hasan A, Abraham WT. A novel approach using phrenic nerve stimulation to treat central sleep apnea. Firstin-Man Experience, 24th Annual Meeting of the Associated Professional Sleep Societies, LLC, San Antonio, Texas, June 2010. 8. Mulder M, Bart BA, Smith SW. Faster, cooler, better? A comparison of two methods for instituting mild therapeutic hypothermia in comatose, out-of-hospital cardiac arrest patients. Poster Presentation, American College of Cardiology, Scientific Sessions, Atlanta, Georgia, March 2010. 9. Ponikowski P, Zhang S, Witkowski T, Hasan A, Khayat R, Bart B, Jagielski D, Zhang X; Central sleep apnea events are terminated by phrenic nerve stimulation. Poster Abstract, American College of Cardiology 59th Annual Scientific Session, Atlanta, Georgia, March 2010. J Am Coll Cardiol. 2010;55(10s1):A30.E289-A30.E289. 10. Thorsgard M, Bart B, Bachour F. The use of elective vs. urgent or emergent PCi from a tertiary teaching medical center. Lillehei Heart Institute Symposium, University of Minnesota, Minneapolis, Minnesota, October 2009. 11. Bart BA. Predictors and significance of decrease in serum creatinine in heart failure patients treated for volume overload with diuretics or ultrafiltration. 12th Annual Scientific Meeting of the Heart Failure Society of America, Toronto, Ontario, Canada, September, 2008. 12. Mulder M, Franco MP, Smith S, Goldsmith SR, Bart BA. Potential impact for therapeutic hypothermia for adult out-of-hospital cardiac arrest survivors at HCMC. 25 10th Annual Department of Medicine Research Day, University of Minnesota, Minneapolis, Minnesota, May 2008. 13. Henry T, Satran D, Campbell A, Johnson R, Poulose A, Hodges J, Bart BA, et al. Long-term mortality in patients with refractory angina. Poster Abstract, American College of Cardiology 57th Annual Scientific Session, Chicago, Illinois, 2008. 14. Guglin ME, Bart BA, Fang J, et al. Predictors and significance of decrease in serum creatinine in heart failure patients treated for volume overload with diuretics or ultrafiltration. J Card Fail. 2008;16(6)Suppl1:S72. 15. Henry, TD, Satran D, Campbell AR, Johnson RJ, Poulose AK, Hodges J, Bart BA, et al. Long-term mortality in patients with refractory angina. J Am Coll Cardiol. 2008;51(10)SupplA:A227. 16. Bart BA, Fang, JC, Guglin M. Changes in GFR, BUN and BUN/creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics. J Am Coll Cardiol. 2008;51(10)SupplA:A48. 17. Bart BA, Insel J, Goldstein MM, et al. The improved outcomes following ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to increased weight loss in the ultrafiltration group. J Card Fail. 2007;13(6)Suppl2:S188(399). 18. Costanzo MR, Bart BA, Anderson A, Sobotka PA. Differential response to ultrafiltration and intravenous diuretics in decompensated heart failure patients with preserved versus reduced systolic function. J Card Fail. 2007;13(6)Suppl2:S180(368). 19. Bart BA, Teerlink JR, Costanzo MR, Saltzberg MT, Sobotka PA. Changes in serum creatinine during treatment of heart failure and volume overload with ultrafiltration or intravenous diuretics. J Card Fail. 2006;12(6)Suppl:S114. 20. Thakkar BV, Hirsch AT, Bart BA, et al. The efficacy and safety of EECP in patients with peripheral arterial disease., American College of Cardiology, Scientific Sessions, Atlanta, Georgia, 2006. J Am Coll Cardiol. 2006;47(4)SupplA:348A. 21. Campbell AR, Zenovich AG, Campbell KM, Espel JC, Streufert TL, Poulose AK, Boisjolie CR, Juusola K, Bart BA, Henry TD. Enhanced external counterpulsation provides acute and sustained hemodynamic benefits in refractory angina. Electronic Poster Presentation, TCP Scientific Sessions, 2006. 22. Smith SW, Jackson EA, Hanson KK, Bart BA. Incidence of MI in ED chest pain patients with a recent negative stress imaging test. Poster Presentation. Society of Academic Emergency Medicine. 2005;12(5). 26 23. Shroff GR, Bart BA. Radiation-induced myocardial dysfunction: a "stunning" phenomenon. Poster Presentation, American College of Physicians-Minnesota Chapter, Scientific Sessions, Minneapolis, Minnesota, 2004. 24. Bogonko E, Larsen K, Bart BA. An "irregular" manifestation of hypoglycemia: a unique case of atrial fibrillation in a young diabetic. Poster Presentation, American College of Physicians-Minnesota Chapter, Minneapolis, Minnesota, 2004. 25. Bart BA, Boyle A, Bank AJ, et al. Randomized controlled trial of ultrafiltration versus usual care for hospitalized patients with heart failure: preliminary report of the RAPID trail. Moderated Poster Presentation, Heart Failure Society of America, Toronto, Ontario, Canada, 2004. J Card Fail. 2004;10(4)Suppl:S23. 26. Mohn JN, Asinger RW, Herzog CA, Bart BA. Echocardiographic correlates in 2337 patients with pulmonary hypertension., American College of Cardiology, New Orleans, Louisiana, March 2004. J Amer Coll Cardiol. 2004;43(5)Suppl A:518A. 27. Bardo A, Bart BA. Something doesn’t click: two cases of sub-acute prosthetic valve thrombosis. Presented at American College of Cardiology Clinical Vignettes, November 2003. 28. Shroff G, Hanchate V, Chaubal N, Bornstein B, Bart BA, Karnad D. Noninvasive measurement of stiffness of large arteries in Takayasu’s disease using the stiffness index. Presented at American College of Cardiology Clinical Vignettes, November 2003. 29. Schneider E, Bart BA. Balanced ischemia: a not so fine balance. Presented at American College of Cardiology Clinical Vignettes, 2003. 30. Schneider E, Bart BA. Balanced ischemia: a not so fine balance. Winner, Regional American College of Physicians Poster Session, Minneapolis, Minnesota, 2002. 31. Koralesky A, Bart BA, Apple F, Henry TD, et al. Is troponin I a risk factor for poor outcome in pulmonary embolus? Presented at World Congress of Cardiology, Sydney, Australia, May 2002. 32. Bart BA, Erlien DD, Asinger RW, Stuart DD, Herzog CA. Differential selection of stress echo and stress SPECT studies in patients with known or suspected ischemic heart disease. J Nucl Cardiol. 2002;9(4):2.27. 33. Koralesky A, Bart BA, Apple F, Henry TD. Is troponin I a risk factor for poor outcome in pulmonary embolism? J Amer Coll Cardiol. 2002;39(5):212A. 34. Herzog CA, Huiras BE, Bart BA. Are nuclear myocardial perfusion and echocardiography (ECHO) stress imaging studies equivalent in the assessment of coronary artery disease in patients with end stage renal disease? J Am Soc Nephrol. 2001;12(2):383A-384A. 27 35. Bart BA, Herzog CA, Boisjolie CR, Peterson-Norby K, Henry TD. Stress echocardiography and nuclear perfusion imaging to assess response to angiogenesis therapy: a double-blind, placebo controlled clinical trial. J Amer Coll Cardiol. 2001;37(2):A7. 36. Henry TD, McKendall GR Azrin MA, Lopez JJ, Benza R, Willerson JT, Giacomini J, Olson R, Bart BA, Roel JP, Annex BH. VIVA trial: one year follow up. Circulation. 2000;102:II-309. 37. Satran A, Bart BA, Murad B, Henry T. Prevalence of coronary artery aneurysm in cocaine users. American Heart Association Scientific Sessions. Circulation. 1999;100:I-557. 38. Whellan DJ, Shaw LK, Bart BA, et al. Cardiac rehabilitation is associated with improved survival in CHF patients. Circulation. 1998;98(1)Suppl I:I-774. 39. Satran A, Bart BA, Murad B, Henry T. Prevalence of coronary artery aneurysm in cocaine users. Presented at State and National American College of Physicians Meetings, September 1998. 40. Larsen RL, Murdock DD, Skyes AM, Barrett SK, Hansley KM, Bart BA, et al. Are there biases against recruitment of the elderly and women in congestive heart failure (CHF) trials? Council on Geriatric Cardiology, Atlanta, Georgia, 1998. 41. Bart BA, Ertl G, Kuch J, et al. Contemporary management of patients with left ventricular dysfunction: preliminary results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. Poster Presentation, 19th Congress of the European Society of Cardiology, Stockholm, Sweden, August 1997. Eur Heart J. 1997;18(abst. sup):402. 42. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O’Connor CM. Is optimal ACE inhibitor dosing neglected in elderly heart failure patients? Poster Presentation, Council on Geriatric Cardiology, 3rd Annual Scientific Session, Anaheim, California, 1997. Am J Geriatr Cardiol. 1997;6:44. 43. Bart BA, Diem SJ, O’Connor CM. Why are heart failure patients with left ventricular dysfunction not receiving angiotensin-converting enzyme inhibitors? J Am Coll Cardiol. 1997;29(2)Suppl A:167A. 44. Bart BA. Study of patients intolerant to converting enzyme inhibitors (SPICE): overview and trial design. 1st Place Poster, 15th Edward S. Orgain Cardiovascular Symposium, Durham, North Carolina, 1996. 45. Bart BA, Shaw LK, McCants CB Jr, et al. The clinical and angiographic diagnosis of ischemic cardiomyopathy: a need to reassess our diagnostic criteria. 28 Poster Presentation, 69th Scientific Sessions of the American Heart Association, New Orleans, Louisiana, 1996. Circulation. 1996;94(8):I-338. 46. Chin MH, Connors AF Jr, Vidaillet H, Phillips R, Bellamy P, Bart BA, Goldman L. Predicting six-month mortality in patients admitted with severe congestive heart failure. Annual Meeting of the Society for Medical Decision Making, Toronto, Ontario, Canada, 1996. 47. Bart BA, Galanos AN, Mooney R, O’Connor CM. Elderly patients admitted for heart failure receive less aggressive care than their younger counterparts. Poster Presentation, Council on Geriatric Cardiology 2nd Annual Scientific Session, Orlando, Florida, 1996. Am J of Geriatr Cardiol. 1996;5(2):58. 48. Vance JC, Bart BJ, Bart BA, et al. Effectiveness of intralesional human recombinant alfa-2b interferon (Intron-A) for the treatment of patients with condyloma acuminatum. Clin Res. 1986;34(4):993A. 29 Bradley A. Bart, M.D., F.A.C.C. 7. SERVICE a. Percent effort 60% b. Narrative Summary As a clinical cardiologist and Director of the Division of Cardiology at Hennepin County Medical Center (HCMC), the focus of my service to HCMC and the University of Minnesota has been on providing excellent clinical care and supporting the educational mission of HCMC and the University of Minnesota, as well as a fulfilling a number of leadership roles. I have been Director of the Division of Cardiology at HCMC since 2008, leading a group of 10 cardiologists who provide cardiovascular services to Hennepin Healthcare System, Inc., including preventive cardiology, interventional cardiology, electrophysiology, heart failure management, inpatient consults, advanced imaging (including CT, MRI, echo, and nuclear), and cardiac rehabilitation. This is a diverse group of physicians with backgrounds representing Ethiopia, Pakistan, India, Syria, and the United States. In my role as Director of the Division of Cardiology, I oversee operations with the medical directors and administrators in the inpatient service areas, cardiology clinic, echo lab, cardiac catheterization lab, electrophysiology lab, ECG lab, and cardiac rehabilitation. In January of 2013, I was asked by the Chief of Clinical Operations and the Chief Nursing Officer for Hennepin Healthcare Systems to serve as the co-lead of a new cardiovascular service line at HCMC - integrating the activities of the Division, critical care, and cardiovascular surgery. In this capacity, I have developed an organizational structure and reporting process that has enhanced communication across the service line and established protocols, reporting tools, quality metrics, and a strategic plan for growth focusing on improving access for primary care. I have also served on a number of hospital committees and working groups. I was elected to the Hennepin Faculty Associates Board of Directors and served the physician practice group representing the Department of Medicine from 2000 to 2003 and again from 2011 to 2012. I was a member of the Minnesota Medical Research Foundation Peer Review Committee, the Chief of Medicine and the Chief of General Internal Medicine Search Committees, and the Core Measures Working Groups for Heart Failure and Acute Myocardial Infarction. The hospital (HCMC) and the physician practice group (HFA) integrated in 2012 to become Hennepin Healthcare System, Inc. (HHS). I was elected by my peers to serve on the Physicians' Compensation and Benefits Subcommittee (PCBS). This committee, including 4 voting physicians, developed the physician compensation and incentive plan that was recommended to the HHS Board of Directors after integration. The PCBS continues to meet to review and revise recommendations to the HHS Board concerning compensation. I also serve on the Graduate Medical Education Committee representing the Department of Medicine and the Fellowship Training Program in Cardiovascular Disease as the Program 1 Director; and am the Co-Chair of the heart failure and acute myocardial core measures working groups. I am an Associate Editor for the Journal of Cardiac Failure, on the Editorial Board for the Journal of the American College of Cardiology, and review papers for the European Journal of Cardiology, Circulation Heart Failure, and the American Heart Journal. I also served on the NHLBI Heart Failure Network Ancillary Studies Committee from 2008 to 2012. My clinical activities consume approximately 50-60% of my time. I served as the medical director for nuclear cardiac imaging at both the University of Minnesota, from 2001 to 2007, and Hennepin County Medical Center from 1997 to the present. I started several clinical programs at Hennepin County Medical Center and continue to serve as medical director for these initiatives, which include the enhanced external counterpulsation program for patients with chronic ischemic heart disease, therapeutic hypothermia for survivors of out of the hospital cardiac arrest, and slow continuous ultrafiltration for patients with acute heart failure. Clinically, I attend on the inpatient cardiology consultation 10 weeks per year, see patients in clinic 3 - 4 half days per week including heart failure clinic, primary cardiology clinic, early access clinic, and outreach clinic in Brooklyn Center. I also read ECGs 5 days per month and cardiac CT and myocardial SPECT studies 6 days per month. I have been active in community educational efforts, including presenting at a number of programs throughout the region including: Grand Rounds at the University of Minnesota, the VA Medical Center, Abbott Northwestern Hospital, Mercy Hospital, St. Paul Heart Clinic, North Memorial Hospital, and the University of Illinois. I have been invited to give talks at the Health Partners Annual Cardiovascular Conference, the Minnesota Chapter of the American College of Cardiology, the East Minneapolis Downtown Council, the Annual Lillehei Symposium, the Annual Bakken Symposium, and the Minnesota Radiological Society. I have been on the Advisory Board of the Minnesota Heart Failure Consortium since its founding in 2002. In this role, I help plan the annual continuing medical education meetings and frequently speak at this well-attended CME-accredited meeting for physicians and nurses. I have spoken in the Heart-to-Heart lunchtime health series sponsored by the Minneapolis Medical Research Foundation in downtown Minneapolis and have had numerous appearances on local radio (Healthy Matters, WCCO), television, and newspapers for cardiology related topics of interest to the lay public. c. Clinical Service Clinical Leadership Accomplishments Established a Cardiovascular Service Line at Hennepin County Medical Center in 2013. Established Fellowship Training program in cardiovascular disease at Hennepin County Medical Center in 2011. Served as Chief of Cardiology at Hennepin County Medical Center since 2008. Established therapeutic Hypothermia Program (first in Minnesota) for cardiac arrest patients at Hennepin County Medical Center, 2004. 2 Established Ultrafiltration Program (first in Minnesota) for acute heart failure at Hennepin County Medical Center, 2004. Established Enhanced External Counterpulsation Program (first in Minnesota) for severe ischemic heart disease at Hennepin County Medical Center, 2002. Established the Nuclear Cardiac Imaging Program and clinical database for nuclear stress testing at Hennepin County Medical Center, 1997. Quality Improvement Projects Co-Chair of Heart Failure and Acute MI core measures working groups – achieving > 95% compliance with core measures in these areas. Co-Chair of Cardiovascular Service Line improving surgical outcomes and increasing growth by 23% in first year of program. Clinical service responsibilities o 10 weeks per year attending on inpatient cardiology consultation service o 3-4 half days of clinic per week (personal, heart failure, early access, and outreach) o ECG reading 5 days/month o Nuclear perfusion imaging and coronary CT angiography 6 days/month. d. Discipline-Related, Professional Service Editorships/Journal Reviewer Experience Reviewer, Circulation: Heart Failure Editorial Board Member, Journal of the American College of Cardiology: Heart Failure Associate Editor, Journal of Cardiac Failure Reviewer, European Journal of Heart Failure 2010-Present 2000-Present Other Service Experiences Steering Committee for AVOID HF clinical trial Member, Advisory Board, Minnesota Heart Failure Consortium Member, International EECP Patient Registry Writing Group 2008-Present 2002-Present 2001-2007 2012-Present 2012-Present Review Panels for External Funding Agencies, Foundations, etc. Ancillary Studies Committee for the NIH/NHLBI Heart Failure Network 2008-2012 Organization of Conferences, Workshops, Panels, Symposia Member, Advisory Board of Minnesota Heart Failure Consortium, assisted in planning annual CME accredited educational symposia Committee Memberships Member, Physician Compensation and Benefits Subcommittee for Hennepin Healthcare System (HHS), Inc., Board, Minneapolis, Minnesota 3 2002-Present 2012-Present Member, Graduate Medical Education Committee, Hennepin County Medical Center, Minneapolis, Minnesota 2011-Present Member, Board of Directors, Hennepin Faculty Associates, Minneapolis, Minnesota 2011-2012 Hospitals and Communities Moving Forward with Patient and Family Centered Care, Madison, Wisconsin 2011 Member, Search Committee for the Director of the General Internal Medicine Division, Hennepin County Medical Center, Minneapolis, Minnesota 2009 Co-Chair, Heart Failure Core Measures Working Group, Hennepin County Medical Center, Minneapolis, Minnesota 2008-Present Co-Chair, Acute MI Core Measures Working Group, Hennepin County Medical Center, Minneapolis, Minnesota 2008-Present Ancillary Studies Committee for the NIH/NHLBI Heart Failure Network 2008-Present Member, Minnesota Medical Research Foundation Peer Review Committee, Minneapolis, Minnesota 2001-2012 Member, Chair of Internal Medicine Search Committee, Hennepin County Medical Center, Minneapolis, Minnesota 2001 Member, Board of Directors, Hennepin Faculty Associates, Minneapolis, Minnesota 2000-2003 Member, Cardiology/IRIS Committee, Hennepin County Medical Center, Minneapolis, Minnesota 2000 Member, Internal Medicine/Hennepin Faculty Associates Cardiology Task Force, Minneapolis, Minnesota 2000 Member, Medical Service Quality Improvement Committee, VA Medical Center, Denver, Colorado 1993-1994 Chair, Timeliness and Delinquencies Subcommittee of the Medical Record Committee, VA Medical Center, Denver, Colorado 1993-1994 Department/Unit Service Co-Chair, Cardiovascular Service Line, Hennepin County Medical Center, Minneapolis, Minnesota 4 2013-Present Program Director, Cardiology Fellowship, Hennepin County Medical Center, Minneapolis, Minnesota 2011-Present Director, Division of Cardiology, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota 2008-Present Co-Chair, Acute MI Core Measures Working Group, Hennepin County Medical Center, Minneapolis, Minnesota 2008-Present Co-Chair, Heart Failure Core Measures Working Group, Hennepin County Medical Center, Minneapolis, Minnesota 2008-Present HCMC Site Rotation Director for University of Minnesota Cardiology Fellowship Program, Hennepin County Medical Center, Minneapolis, Minnesota 2001-2010 Member, Hennepin Faculty Associates, Board of Directors, Minneapolis, Minnesota 2011-2012 2000-2003 e. University Service Member, Cardiology Fellowship Selection Committee, University of Minnesota, Minneapolis, Minnesota 2001-2010 Rotation Director, Nuclear Cardiac Imaging Rotation for Cardiology Fellows, University of Minnesota, Minneapolis, Minnesota 2002-2007 University of Minnesota Cardiology Fellowship Selection Committee, University of Minnesota, Minneapolis, Minnesota 2001-2010 f. Other Service Community Outreach Activities 1. Interview, “HCMC Doctor Warns Shoveling Snow Can Lead to Heart Attacks.” Channel 5 Eyewitness News, Minneapolis, Minnesota, February 20, 2014. http://kstp.com/article/stories/s3334039.shtml 2. Interview, “Are marathoners running into heart trouble?” Article by Jeff Strickler, Star Tribune, Minneapolis, Minnesota, June 14, 2013. http://www.startribune.com/lifestyle/health/211578741.html 3. Speaker, Annual Bakken Symposium 2010 4. Guest, WCCO News Radio “Healthy Matters with Hennepin County Medical CenterHeart Health,” Minneapolis, Minnesota, February 8, 2009. 5 5. Medicine Grand Rounds at the University of Minnesota, VA Medical Center, Abbott Northwestern Hospital, Mercy Hospital, St. Paul Heart Clinic, North Memorial Hospital, and the University of Illinois. 6. Speaker, HealthPartners Annual Cardiovascular Conference 2005, 2008 7. Speaker, East Minneapolis Downtown Council 2004 (one presentation) 8. Speaker, Annual Lillehei Symposium 2004, 2009 9. Speaker, Heart-to-Heart Lunchtime Health Series sponsored by the Minneapolis Medical Research Foundation 2004, 2005 (one time per year) 10. Speaker, Minnesota Radiological Society 2000 (one presentation) Miscellaneous interviews with local TV, newspapers, and magazines including StarTribune, St. Paul Pioneer Press, Minneapolis/St.Paul Magazine, Minnesota Monthly, Minnesota Business Monthly. 6